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Abstract
Unfixed human breast tissue obtained prospectively from
biopsy and mastectomy specimens was supravitally stained
with methylene blue to select areas of altered parenchyma
in which ras expression was studied by immuno-
histochemistry. The monoclonal antibody Y13-259 binds to
an epitope common to all three p21 ras proteins. Y13-259
immunoreactivity did not survive formaldehyde fixation
and paraffin embedding but fixatives periodate-lysine-
paraformaldehyde (PLP) and its dichromate derivative
(PLPD) preserved immunoreactivity and good morphology in
paraffin sections. Rodent fibroblasts (CHL cells) and
derived cells expressing abundant p21 ras (FH05T1 cells)
provided negative and positive controls for avidin-
biotin-complex immunostaining. A semi-quantitative score
was devised and validated to express and compare
immunostaining results for 99 women with carcinoma and 72
women with benign changes.
Expression of p21 ras was the same in large ducts, small
ducts and terminal duct lobular units (TDLU). Intensity
and extent of epithelial immunostaining for p21 ras
increased in the sequence normal - ductal hyperplasia
without atypia - atypical hyperplasia - ductal carcinoma
in situ. Lobular hyperplasias showed a similar increase.
There was no difference in p21 ras expression between
non-invasive and invasive carcinomas. In normal
parenchymal epithelium, p21 ras score was the same in
women with cancer and women with benign changes only, but
decreased with age. 20 carcinomas with vascular invasion
showed stronger p21 ras immunostaining of carcinoma cells
surrounded by stroma than carcinoma cells within vascular
lumina. This may reflect interaction between malignant
and stromal cells. There were no differences between p21
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ras scores of carcinomas with vascular invasion or lymph
node metastasis and those without. Membrane staining of
FH05T1 cells in culture or growing as tumours in mice
contrasted with cytoplasmic staining in optimally fixed
and processed human material. Human carcinomas may
therefore express abundant cytoplasmic p21 ras.
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Chapter 1
CHAPTER 1 GENERAL INTRODUCTION
Breast carcinomas develop by unknown mechanisms from
small epithelial lesions. Oncogene abnormalities have
been found in human carcinomas and while experiments with
cell lines and transgenic animals are very fruitful in
suggesting hypotheses about human cancer, it is only by
examining human material that these hypotheses can be
tested directly. The present studies are concerned
exclusively with human breast tissue and in particular
with putative precursor lesions in which oncogene
expression may correlate with abnormal morphology to
illuminate the processes by which carcinomas evolve. An
attempt has been made to develop methods for isolation
and study of such lesions, in which expression of the
products of the ras proto-oncogene family has been
examined in detail.
In general, the identification of precursor lesions rests
upon their morphological similarities with carcinoma, co¬
occurrence with carcinoma, and on the increased risk of
subseguent breast carcinoma among women shown by biopsy
to have these alterations in the absence of demonstrated
carcinoma. Before considering these lesions in detail,
it is helpful to review the normal anatomy of the adult
female breast, from which these lesions deviate. The
nomenclature for different parts of the parenchymal tree
varies between authors but that given below is
essentially that used by Dawson [26] and Wellings and
Jensen [151].
1.1 Normal breast anatomy
Between a dozen and a score of major ducts reach the
nipple and each engenders a complex hierarchy of smaller
- 16 -
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ducts ramifying throughout the breast. The terminal
ducts are distal to the last duct bifurcation but
proximal to the lobules. Lobules are the individual
glandular elements of the breast and are composed of
branching ductules embedded in specialized myxoid stroma.
Ductules and terminal ducts share the ability to undergo
secretory differentiation and can be considered together
as terminal duct lobular units (TDLU).
These relationships are illustrated in figure 1.1a, a
schematic section through breast and nipple. Only four
major ducts are shown reaching the nipple but an enlarged
section (figure l.lb) through the nipple perpendicular to
the ducts depicts a representative number. The branching
duct system arising from one large duct is illustrated
down to the lobules, represented by small ellipses joined
to the ductal tree by terminal ducts. The ducts tend to
radiate from the nipple, but the breast is not segmental
and duct territories overlap. The parenchymal elements
(ducts and lobules) are supported by collagenous stromal
connective tissue which is physically continuous with
fascia deep to the breast and attached to skin by the
suspensory ligaments of Astley Cooper. The remainder of
the breast is fat. Ratios of parenchyma, collagenous and
adipose connective tissue vary from woman to woman and
with age. Figures 1.1c and l.ld show the arrangement of
a duct, terminal duct and lobule composed of numerous
ductules. Figure 1.1c shows the structure in three
dimensions while figure l.ld shows the appearance
characteristic of histological sections in which
connections between elements are not apparent.
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Figures 1.1a and b. Diagrammatic section through adult
female breast and section through nipple showing
arrangement of major ducts.
Figure 1.1c. Three-dimensional structure of terminal duct
lobular unit. 1, large duct. 2 and 3, extra- and intra¬
lobular terminal ducts. 4, ductules. 5, boundary of
specialized lobular connective tissue. Figure l.ld.
Terminal duct lobular unit in histological section.
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1.2 Histogenesis of breast carcinoma
The evolution of carcinoma from breast epithelium remains
mysterious. Even such concrete matters as the
morphological stages passed through, which alterations in
the breast are associated with increased risk of breast
carcinoma, and which lesions are authentic precursors of
carcinoma are uncertain. The chief reasons for this
doubt are the multiplicity of alterations, the
impossibility of studying the temporal evolution of a
particular lesion in a particular breast, and the
destruction by invasive carcinomas of surrounding
tissues, obliterating earlier stages of the evolutionary
process. Despite these difficulties, much has been
learned, and in the next sections available evidence will
be reviewed to provide the foundations for the studies to
be described subsequently.
1.3 'Fibrocystic disease' and carcinoma
For long the relation between carcinoma and the complex
of morphological alterations known among other names as
'fibrocystic disease' has been debated, and strongly
opposed views held. Authors have approached this
question in various ways, and some of these approaches
are discussed in the following sections.
1.3.1 Histological transitions between benign and
malignant epithelium
Transitions between non-malignant and malignant
epithelium could theoretically provide direct evidence
for the origin of carcinoma in the breast, but for
several reasons such transitions have not been
convincingly demonstrated. As already noted, invasive
- 19 -
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carcinomas destroy tissues, and cover their traces. An
invasive carcinoma five millimetres in diameter, tiny in
clinical terms, may already be many times larger than the
parent lesion in which it developed. Secondly, non¬
invasive carcinomas colonise benign parenchymal elements,
displacing and replacing original populations of
epithelial cells, hence malignant cells may lie in
locations far from their origin, in contact with
populations of cells which had nothing to do with their
genesis. It is a rare 'transition' that on morphological
grounds alone can be distinguished from a collision of
disparate elements.
A different type of transition would exist if a
morphological continuum could be shown between normal
parenchyma, through a range of alterations sharing
structural features with malignant lesions, one blending
imperceptibly into the next, until unequivocally
malignant lesions are reached. Wellings, Jensen and
their colleagues have constructed two models of the
evolution of different types of breast cancer
[106,134,151]. They define five grades of 'atypical
lobule type A' (ALA I-V), grade V being ductal carcinoma
in situ (DCIS), and five grades of 'atypical lobule type
B', grade V being lobular carcinoma in situ (LCIS). But
the impossibility of extrapolating from static to dynamic
description is a drawback, and not all authors accept
that these morphological alterations represent an
authentic biological continuum. Azzopardi, for instance,
denies that ALA III and ALA IV are similar enough to
establish a continuum [3]. The morphological definitions
of these lesions will be discussed in 1.4, where their
relationship to alternative classifications will be





In an attempt to discover whether breast carcinoma was
preceded by significant pathology, Foote and Stewart [38]
determined the frequency of earlier breast operations in
1200 women with breast cancer. 2.4 per cent of women with
breast cancer had a recorded breast operation for benign
changes, an incidence 2.2 times that for women with
other, non-mammary cancers. But when questioned, four
per cent of the women with breast cancer recalled
previous breast operations. This discrepancy illustrates
one of the weaknesses of retrospective studies. Haagensen
believed that it was impossible to determine accurate
information from such studies [58]. Steinhoff and Black
[126] attempted to rectify this defect by reviewing the
original benign biopsies of thirty women who later
developed breast cancer and comparing the findings with
those of thirty age-matched controls, but such small-
scale studies do not yield convincing results.
1.3.3 Prospective studies
In reviewing a number of prospective studies, Azzopardi
[3] noted that many are best described as 'prospective
observational studies done in retrospect'. The
subsequent fate of women who have had benign biopsies in
the past is determined. Modern diagnostic criteria can
be applied to the review of available pathological
material, but the selection of material for examination,
fixation and processing are of course immutable. It is
assumed that the excised tissue is representative of
pathological changes in the breast but does not
necessarily include all pathological tissue present in
the breasts. Nevertheless such studies currently provide
the best assessments of the cancer risks associated with
- 21 -
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different morphological alterations in the breast. Many
older studies predate precise criteria distinguishing
epithelial hyperplasia from carcinoma iri situ and even
the recognition of lobular carcinoma in situ. which was
described in 1941 by Foote and Stewart [39]. These
difficulties effectively disqualify, for example, the
studies by Warren in 1940 [148] and Clagett et al in 1944
[20], and lobular carcinoma in situ was rarely recognised
by 1954 when Kiaer [72] published his studies. Against
this background exhaustive recent studies of the
component parts of the 'fibrocystic disease' complex by
Page et al [33,97], using modern criteria, have given
particularly valuable information and it is appropriate
to review their findings in some detail.
Page et al [33] studied 10,366 consecutive breast
biopsies done at three Nashville hospitals up to 1968.
These yielded a group of 2408 biopsies showing
proliferative changes or carcinoma in situ, but not
invasive carcinoma, with 2011 control biopsies lacking
such changes. These 4419 biopsies were from 3318 women
for whom adequate material for pathological reassessment
and follow-up for a minimum of seventeen years were
available. The 'proliferative' group were divided into
the diagnostic categories in table 1.1.
'Non-proliferative' diagnostic categories included mild
hyperplasia of usual type, cysts, parenchymal
microcalcification, fibroadenoma, and papillary apocrine
metaplasia. The morphological criteria used are those of
McDivett [84] for in. situ carcinoma, and similar to those
of Jensen et al [67], Wellings et al [150], and Black and
Chabon [10] for other lesions. The findings are
summarised in table 1.2 which gives the cancer risk
associated with various proliferative morphological
- 22 -
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Ductal carcinoma in situ (DCIS)
Lobular carcinoma in situ (LCIS)
Atypical ductal hyperplasia (ADH)
Atypical lobular hyperplasia (ALH)
Moderate and florid hyperplasia of usual type
Papillomas
Ductal involvement with cells of ADH
Sclerosing adenosis
Table 1.1. Diagnostic categories used by Page et al
[33,97] .
Relative risk
Proliferative disease without atypia 1.9 (1.2-2.9)
typical hyperplasia, overall 5.3 (3.1-8.8)
Atypical hyperplasia, no FH 4.3 (2.4-7.8)
Atypical hyperplasia, with FH 8.4 (2.6-27)
Table 1.2. Risks of subsequent carcinoma in women with
various hyperplastic states in the breast relative to
women without proliferative changes on breast biopsy.
From [33]. Bracketed figures are 95% confidence limits.
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alterations relative to the risk for women with
nonproliferative (NP) changes only. The 95% confidence
intervals for these estimates are also given.
In a more detailed analysis [97], atypical ductal
hyperplasia (ADH) was separated from atypical lobular
hyperplasia (ALH), and the effects of family history (FH)
were considered, to give the relative risks shown in
table 1.3.
In summary, for women with ADH or ALH the risk of
subseguent breast cancer was about five times that for
women without proliferative changes, in whom the risk was
the same as in the general population. If there was a
history of breast cancer in a first degree relative, that
risk doubled, and was almost the same as the risk
associated with in situ carcinoma, which for DCIS and
LCIS is eleven-fold that of the general population
[57,98,104]. A point worth noting is that the lesions
designated 'atypical' in these studies have distinct
morphological resemblances to carcinomas in situ♦ Others
have used 'atypical' for all hyperplasias [10,150] and it
is important to appreciate this. Women with
proliferative changes but no atypia had about twice the
cancer risk of the general population.
Haagensen [58] has considered that 'gross cystic disease'
is a risk factor for subseguent carcinoma. The studies
just discussed did not find that cysts were an
independent risk factor but were associated with doubled
risk in women with a positive family history.
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ALH with FH NP, no FH
NP with FH
NP, no FH
Table 1.3. Risks of subsequent carcinoma in women with
various hyperplastic states in the breast relative to
women without proliferative changes on breast biopsy and
including the effects of family history of carcinoma.
From [97]. Bracketed figures are 95% confidence limits.
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1.4 Evolution of carcinoma: Subgross studies
The comprehensive studies by Wellings, Jensen and their
colleagues also provide valuable evidence concerning the
evolution of breast carcinoma [151]. They examined
nearly two hundred intact fixed mastectomy and autopsy
breasts sliced at 2mm intervals, stained with
haematoxylin and cleared in methyl salicylate. All areas
where the parenchyma departed from the normal
'background' lobular morphology were photographed and
processed for paraffin histology. They considered that
this approach identified all parenchymal lesions and
permitted their histological examination in 5-500
paraffin blocks per breast.
The most significant finding was that most parenchymal
alterations in the breast arose in terminal duct lobular
units (TDLU) or the lobules themselves. The only
exception was intraduct papilloma developing in large
ducts. As well as benign changes such as cyst formation
they identified two series of atypical lobules, type A
and type B. It is important to note that 'atypical' is
being used here in a sense different to that used by Page
et al, but similar to the usage of Black and Chabon [10],
meaning any lobular alteration. Atypical lobules type A
(ALA) were commoner in the breasts of women with breast
cancer and could be arranged morphologically in a
continuum with DCIS. As DCIS was approached atypical
lobules expanded and 'unfolded' to give the false
impression that DCIS was a ductal lesion (figure 1.2a-d).
These morphological findings were taken to support the
hypothesis that 'ALA' were premalignant lesions. The
atypical lobule type B (ALB) continuum was based on
relatively few cases, but stood in the same relation to
LCIS as ALA to DCIS. The work of Jensen and her
- 26 -
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Figure 1.2. 'Unfolding' of a lobule to simulate a ductal
structure. The ductules are progressively dilated and
coarsened until finally they are lost. If the plane of
histological section no longer identifies a terminal duct
(d) the illusion is complete. These morphological




colleagues represents the most determined attempt to
establish the precursors of human breast cancer by
morphological criteria. While the detailed histological
series (ALA I-V and ALB I-V) have not been universally
accepted and indeed this nomenclature was later abandoned
by Alpers and Wellings [1], proof of the origin of breast
carcinoma in lobules was of paramount significance.
Differences concerning what constitutes in situ carcinoma
certainly exist between authors. Azzopardi [3] was
unconvinced that a continuum had been demonstrated and
considered that ALA grade IV represented ductal carcinoma
in situ. He was reluctant to accept the concept of
atypical hyperplasia. Differences in the incidence of
ostensibly identical lesions in studies by different
authors certainly suggest differences in interpretation.
It is interesting to contrast the findings of Nielsen et
al [93] who processed for histology all breast tissue
from 110 medico-legal autopsies of women aged 20-54.
Their blocks were 5mm thick and their identification of
small lesions may have been less sensitive but using the
criteria of Azzopardi [3] they found DCIS in 15, LCIS in
4, and DCIS and LCIS in one of their cases. A further
two women had invasive carcinoma. Only one of the women
was known during life to have breast cancer. In contrast
to this overall 20 per cent incidence of carcinoma,
Alpers and Wellings' most recent publication [1]
documents ALA grade V (i.e. DCIS) in 5 of 88 women aged
20-59, an incidence of 5.7 per cent. Only two more women
had lesions of ALA grade IV. These 7 women represent 7.9
per cent compared with the 14.5 percent with DCIS of the
women studied by Nielsen et a_l. Either there is a large
difference in the incidence between Denmark and




Fortunately, the studies of Page et al [33,97] provide a
morphological formulation of proven prognostic
significance. Azzopardi's reservations concerning
atypical hyperplasia as a concept are answered by the
demonstration of intermediate risk associated with it,
and a continuum of risk, if not of evolution, was
demonstrated. The histological criteria of Page et al
[33,97] were adopted in this thesis and are reviewed in
the next sections.
1.5 Histopathological criteria for the diagnosis of
breast hyperplasia, atypia and neoplasia
This thesis is concerned with the relationship between
expression of the ras proto-oncogene and the evolution of
breast carcinoma. As discussed above there is no certain
way of identifying the stages of this evolution, although
the importance of lobular epithelium has been stressed.
Because of its proven association with prognosis, and
clearly illustrated diagnostic criteria, I have adopted
the formulation of Page et aJL [33,97], recently expanded
by Page and Anderson [96]. Ensuing sections describe the
key elements of this classification (table 1.4) some
illustrations of which will be provided in chapter 3.
In normal breast parenchyma there are two cells between
basement membrane and lumen. Hyperplasia exists when
this number is exceeded. Abnormally numerous glandular
elements composed of cells retaining the usual relation
to the basement membrane constitute adenosis, a separate
entity. Mild epithelial hyperplasia begins when an
increased number of cells is present. Sectioning
artefacts may mimic this appearance and the whole unit
must be assessed, not single ductules. More florid




Atypical lobular hyperplasia (ALH)
Ductal involvement by cells of ALH
Lobular carcinoma in situ (LCIS)
2. 'Ductal' changes
Hyperplasia without atypia
Atypical ductal hyperplasia (ADH)
Ductal carcinoma in situ (DCIS)
3. Apocrine metaplasia
Papillary apocrine change
4. Invasive carcinoma including special types
Table 1.4. Hyperplastic, atypical and neoplastic
alterations of breast parenchyma. This is not an
exhaustive list but includes the lesions on which this




containing them. In this formulation, 'atypia' implies
morphological features similar to those of non-invasive
carcinoma while not completely satisfying the criteria
for that latter diagnosis.
1.6 Epithelial hyperplasias without and with atypia
1.6.1 Epithelial hyperplasia of usual type ('Ductal')
Historical precedent has applied the 'ductal' label to
these hyperplasias which affect terminal ducts and
lobular units. They are 'usual' in the sense of being
the most commonly observed hyperplasias in breast while
lacking specific apocrine features or features of
atypical ductal or lobular hyperplasias. Mild
hyperplasia of usual type does not expand parenchymal
elements or bridge or solidly occupy lumina. This change
is present in up to 50 per cent of premenopausal biopsies
and carries no increased carcinoma risk. Moderate and
florid hyperplasias of usual type may occur in 20 per
cent of biopsies. Expansion and luminal bridging are
present and may coexist with 'columnar alteration of
lobules', a change in which the epithelial cells are
abnormally tall, sometimes with secretory snouts, but
hyperplasia is absent by definition because the
epithelium remains two cells thick. The patterns in
moderate and florid hyperplasia of usual type are very
varied. In more florid examples, 'swirling' or
'streaming' of the cells, slit-like spaces, tapering
cellular arches composed of cells elongated parallel to
the arch, cell-to-cell nuclear variability representing
heterogeneous cellular differentiation (but lacking




1.6.2 Atypical ductal hyperplasia
This diagnosis implies architectural or cytological
features of ductal carcinoma in situ but not fulfilling
all criteria for its diagnosis. The most important
features are monotony of cells, smooth geometric spaces
between cells (unlike the irregular slit-like spaces of
benign hyperplasia), and nuclear hyperchromasia. The
swirling pattern is absent. Partial involvement of a
space by cells of DCIS does not qualify for DCIS; Page et
al [97] adopted a rule that two whole spaces should show
the changes of DCIS to secure that diagnosis. Complex
patterns are seen and this area is one of diagnostic
difficulty.
1.6.3 Atypical lobular hyperplasia
Unlike atypical ductal hyperplasia, there is no
corresponding non-atypical lesion, despite the attempt by
Jensen and her colleagues to define such a series, which
was quoted above (section 1.4). As with the definition
of ADH given above there is the possibility of a simple
definition, but some inconsistencies exist in the
literature. The cytological appearance of the cells in
ALH is the same as the cells of LCIS. Page and Anderson
[96] state that when the characteristic cells occupy or
expand less than half of the ductules in a parenchymal
unit, ALH is the diagnosis, not LCIS. Page et aJL [97]
say that the features of LCIS must be present 'throughout
the major portion' of a lobular unit in order for LCIS to
be diagnosed. Stated criteria vary in emphasis even
within the writings of the same authors, and for the
purposes of this thesis complete replacement of the
normal epithelium in a parenchymal unit by the
characteristic cells is taken as necessary and sufficient
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for a diagnosis of LCIS. Preservation of the original
lumen or partial retention of the original cell
population is the usual way in which full criteria for
LCIS are not met. Intracytoplasmic lumina are found in
ALH and LCIS and do not discriminate between these
lesions. Uniform, evenly spaced, small round cells are
characteristic. Pagetoid spread by these cells may be
seen and termed 'ductal involvement by ALH'.
1.7 Carcinoma in situ
1.7.1 Ductal carcinoma in situ
Under this heading three separate patterns are
recognised. Micropapillary and cribriform ductal
carcinoma in situ freguently occur together and
transitions between the two forms are found. Unlike
them, comedonecrotic DCIS is notable for cellular
pleomorphism. Occasionally all three patterns are
present. Lesions vary from less than a millimetre to
massive involvement in all quadrants of the breast.
Solid [2] and signet-ring [36] patterns of DCIS may be
identified but their biological potential is ill-
characterised. To what extent types behave differently
is unclear.
Diagnostic features of the non-comedonecrotic lesions
have been referred to above but for completeness some
details may be added. Micropapillary DCIS is
characterised by regular cellular projections, often
broader at tip than base, lacking a fibrovascular core
(unlike papillary non-invasive carcinomas). Cytology of
both micropapillary and cribriform DCIS is uniform, with
regular punched-out spaces in the latter. Necrosis is
not usually conspicuous in these variants, but is of
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course characteristic of comedonecrotic DCIS. Although
the increased risk of invasive breast carcinoma
associated with DCIS is about tenfold that of the general
population, this risk may be confined to the ipselateral
breast [149], and the prognosis for DCIS without evidence
of invasion after adeguate sampling is excellent [12].
1.7.2 Lobular carcinoma in situ
Lobular carcinoma in. situ is impalpable and usually
invisible in gross specimens. It was more recently
recognised than DCIS and appears to be associated with
equal risk of subsequent invasive carcinoma to either
breast. The characteristic cells have been described
above in section 1.6.3 (atypical lobular hyperplasia)
with the criteria distinguishing it from ALH. LCIS is
characteristically multicentric and lacks necrosis and
may be associated with pagetoid colonisation of duct
epithelium. The ductal lesions associated with ALH or
LCIS are identical and the differential diagnosis can
only be resolved on lobular morphology. Colonization by
cells of DCIS within lobules retaining their usual
archetecture must be differentiated from LCIS. Greater
cellular pleomorphism in this case is usually distinct
from the monotony of the cells of LCIS.
1.8 Invasive carcinomas
Breast carcinomas are histologically diverse, and a
number of characteristic special types are recognised,
but the majority do not possess such features and are
known as ductal carcinomas or carcinomas of 'no special
type'. Recognised special types include lobular,
medullary, mucoid, tubular, tubulo-lobular, cribriform,
and papillary invasive carcinomas.
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1.8.1 Invasive carcinoma (no special type)
Ductal invasive carcinoma is typically composed of
irregular islands of pleomorphic malignant cells in a
fibrous stroma. Glandular differentiation may be present
but features of special types of carcinoma are not
prominent. A carcinoma in which more than half the
section area belongs to no special type should be
regarded as being of no special type overall. These
carcinomas are diverse in appearance and diagnosis rests
on the lack of features belonging to special type
lesions.
1.8.2 Special types of invasive carcinoma
Lobular invasive carcinomas, like LCIS, were first
reported by Foote and Stewart [37]. They are
characterised by cytological and infiltrative pattern and
a number of variants have been described. The classical
infiltrating lobular carcinoma has small, non-cohesive,
regular cells with round nuclei. These cells invade
widely in enfilades. Solid and alveolar variants lack
this infiltrative pattern but retain characteristic
cytology. The mixed variant mingles features of these
types while the diffusely infiltrative pleomorphic
variant lacks cytological regularity. Lobular invasive
carcinoma is often found with LCIS, which cytologically
it resembles.
Despite its capacity for diffuse infiltration, classic
invasive lobular carcinoma has a better prognosis than
carcinoma of no special type, and so do the other special
type carcinomas, one or two of which have a particularly
good outlook. Tubular and cribriform invasive
carcinomas, both characterised by regular nuclear
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morphology and archetecture, belong to this favourable
group. It is curious that medullary carcinoma of breast,
characterised by extreme cellular pleomorphism, also has
a relatively favourable outlook. It is unnecessary to go
into detail about the histological features of these
relatively rare types of carcinoma, but a subjective
element to their assessment should be appreciated,
reflected in the different frequecies with which special
types are recorded in various series.
It is into this morphological framework that this thesis
seeks to fit observations on the expression of genes of
the ras family.
1.9 Ras genes
The remainder of this introduction reviews the biology of
ras genes, in general and as they relate to the breast,
before discussing briefly other oncogenes relevant to
breast neoplasia and ways in which oncogene expression in
breast may be studied. A distinction is observed between
proto-oncogenes and oncogenes. Proto-oncogenes are normal
cellular genes while oncogenes are abnormal forms of
these genes activated by diverse mechanisms including
point mutation. This usage will be observed as far as
possible.
1.9.1 Biochemistry of ras products
Ras genes are responsible for the acutely transforming
activity of the Harvey and Kirsten strains of murine
sarcoma virus. These viral oncogenes (v-Ha-ras, v-Ki-
ras) have four normal homologues in all mammals: The
genes c-Ha-rasl and c-Ki-ras2 and pseudogenes c-Ha-ras2
and c-Ki-rasl. The mammalian N-ras gene was discovered
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by transfection of neuroblastoma DNA into NIH3T3 cells
[112] and has not been found in the genome of a
retrovirus [54]. Analogous genes are found in lower
organisms.
The products of the three ras genes are proteins of
molecular weight 21,000, conventionally known as "p21
ras" proteins. They are closely associated with the
inner face of the plasma membrane, and indeed are
difficult to dislodge from that location [54]. Certain
biochemical activities are constant features of p21 ras
proteins: notably GTP and GDP binding [108,111,130,135]
and weak GTPase activity [46,83,86,128,135]. These
activities are important for physiology of normal ras
proto-oncogene products and for the transforming
properties of ras oncogenes [22,34,155]. It appears that
GTP bound to p21 ras activates it while the GDP-bound
form is inactive.
Evidence for the importance of guanine nucleotide binding
and hydrolysis of GTP to the transforming activities of
ras proteins includes reversion of the transformed
phenotype in NIH3T3 cells transformed by ras genes when
injected with antibodies which inhibit guanine nucleotide
binding [22,34]. Mutant ras proteins incapable of
guanine nucleotide binding are incapable of transforming
NIH3T3 cells [76,155], and transforming mutant ras genes
encode proteins deficient in GTPase activity
[46,83,86,128,135].
The physiological roles of p21 ras proteins remain
unclear [6], Evidence connects them with cell division
[66,77,80,90] but also with differentiation
[5,19,42,55,94]. Microinjection of cultured cells with
ras oncogene products stimulates transient cellular
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proliferation and morphological transformation
[35,65,125], and cells engineered to express
constitutively supranormal quantities of p21 ras proto-
oncogene [18,30,88,100] and oncogene [18,100,120,122]
proteins have a transformed phenotype and will form
aggressive malignant tumours in immune deprived mice
[122,156]. In general the oncogenes induce more floridly
malignant phenotypes than the proto-oncogenes [6].
Direct and indirect evidence link growth factors with p21
ras expression. NIH3T3 cells into which an inducible N-
ras proto-oncogene had been inserted had normal basal
levels of inositol phospholipid turnover but increased N-
ras expression was associated with a supranormal increase
in turnover of inositol phospholipids in response to
bombesin and bradykinin but not to EGF or PDGF [145].
Other ras genes may be associated with increased turnover
in response to other growth factors such as serotonin or
PDGF. Unlike ras proto-oncogenes, overexpressed ras
oncogenes are associated with increased basal turnover of
inositol phospholipids [145], apparently because the GTP-
bound, active form of p21 ras predominates.
There is no clear correlation between ras expression and
cellular proliferation in a variety of tissues [19].
Although regenerating rat liver expresses up to eight
times as much p21 ras as normal liver [53], the rat
tissue expressing most p21 ras is brain [131], while in
mice the tissue richest in p21 ras is cardiac muscle
[120]. The PC12 phaeochromocytoma cell line provides
another link with differentiation. In this line p21 ras
microinjection induces neuronal differentiation
[5,55,94], and neuronal differentiation induced by nerve
growth factor is blocked by microinjection of monoclonal
antibody Y13-259 [59]. Human immunocytochemical studies
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have demonstrated p21 ras in various terminally-
differentiated cells [19,42]. Discovery of GTPase
activating protein, GAP, [14] points towards
understanding of ras protein physiology but many
questions remain.
Abnormally expressed ras genes are common in human
carcinomas, but it is not clear where these abnormalities
occur along the stages that lead to the emergence of a
fully malignant cell , and even how important they are in
spontaneous tumours. The enthusiasm engendered by
initial reports of transforming genes in human tumours
[31,99,106] and the subsequent demonstration of point
mutations in ras genes, apparently responsible for these
transforming properties [102,129,134], was followed by a
more cautious phase [24,116] but since then more refined
genetic analysis has shown that in some locations, such
as colo-rectal and pancreatic carcinomas, ras gene
mutations are frequent [11,40].
1.9.2 Ras genes and experimental neoplasia
Experimental tumour research defines areas significant
for spontaneous human cancer as well as for experimental
lesions. Some significant experiments will be described
here, before considering ras genes and other oncogenes in
their specific relationship to the breast. Spandidos and
Wilkie [122] showed that the mutated Ha-ras gene was
capable of engendering full malignant transformation in
low passage rodent cells, if introduced into those cells
along with transcriptional enhancers. These cells had
the transformed phenotype in vitro and were tumorigenic
in nude mice. They also showed that, while not causing
the transformed phenotype, primary cultures of rodent
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cells were protected from senescence ('immortalised') by
the introduction of either normal ras gene with enhancers
to ensure its expression at high levels, or by the
mutated ras gene without such enhancers. This blurs the
customary distinction between immortalizing and
transforming genes, suggesting that the same gene can be
both under appropriate conditions.
On the basis of what they found in these experiments,
Spandidos and Wilkie [122] proposed a role for ras in
earlier stages of carcinogenesis than had been suggested
previously. Balmain et al [4] noted that papillomas
induced on the skin of mice by repeated application of
chemical carcinogens could contain cellular Ha-ras DNA
capable of transforming NIH 3T3 cells [61]. A specific
mutation is frequently induced by a particular
carcinogenic hydrocarbon [101]. Adenomatous polyps of
colon have elevated ras transcripts [121] and expression
of p21 ras [153]. Wyllie et al showed [156] that cell
lines expressing ras and myc genes both engendered
metastasizing fibrosarcomas when injected into nude mice,
and some interesting differences came to light in this
study. Ras-expressing cells engendered more aggressive
tumours than mvc expressing ones and non-mutated Ha-rasl
was capable of inducing metastasizing fibrosarcomas in an
aneuploid rat fibroblast cell line. Cell death by
apoptosis was more frequent in cells transformed by myc
than ras genes, which is of interest in that cell death
by apoptosis can be very conspicuous in human cancers.
Another observation was that c-abl and c-fos were
strongly expressed in cells transformed by Ha-ras or mvc
genes, implying widespread alterations in metabolic
activity and raising the possibility of co-activation of
complementary oncogene groups [78,87]. It was unclear
whether altered expression of c-fos and c-abl was a
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direct consequence of altered myc or ras expression,
given that other genetic abnormalities might have
accumulated during the selection process by which these
cells were generated, and the transformed cells derived
from primary cultures of Chinese hamster lung (CHL) cells
were aneuploid, while their parent cells were not. On
the other hand microinjection of p21 ras also increased
the expression of these other oncogene products, which
would be in keeping with a direct effect. While not
directly defining a role for oncogenes in the evolution
of spontaneous human malignancies, such experiments do
support a role for these oncogenea and their products.
Interesting results have been obtained with transgenic
animals. Oncogenes have been inserted with promoter
sequences into the genome of such animals and the tissue
effects have been studied. Stewart et aJL [127] created
strains of mice in which the myc gene was coupled to
hormonally-inducible promoters from mouse mammary tumour
virus (MTV). These MTV/mvc genes were associated with
mammary adenocarcinomas which developed in a stochastic
fashion during pregnancy. More recently Sinn et al [115]
have mated MTV/myc and MTV/v-Ha-ras transgenic mice to
create dual carrier mice in which potent synergism of myc
and ras genes was demonstrated, but even in these animals
mammary adenocarcinomas developed stochastically,
indicating that a further event was needed before
malignant transformation was completed. But transgenic
mice bearing MTV/c-neu (c-erbB2) fusion genes develop
synchronous polyclonal malignant transformation
indicating that overexpression of c-neu activated by
mutation is sufficient for single-step malignant
transformation [91]. The contrast is striking.
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1.10 Ras and breast carcinoma
Evidence relating ras genes and their expression to human
breast carcinoma derives from several lines of enquiry.
Published studies have examined the genes themselves, the
RNA they encode, and their p21 protein products.
Researchers have sought gene amplification [9,136], gene
rearrangement [136], quantitative differences in ras RNA
expression between putatively normal breast and
carcinomas [119,152], and activating mutations in ras
genes of carcinomas, by transfection into NIH 3T3 cells
or by generation of restriction endonuclease cleavage
fragments characteristic of particular mutations [9,136].
The p21 ras proteins in breast extracts have been studied
in immunoblots [21,27,132,136], by radioimmunoassay [95]
and immunocytochemically using diverse antibodies
including RAP-5 [41,45,64] and Y13-259 [15,64,95]. Some
consistent themes emerge from these studies but
contradictions abound and the role of ras genes in the
evolution of breast cancer remains unclear. The results
of these and other studies will be reviewed in the next
three parts of this subsection under headings DNA, RNA,
and protein. Table 1.5 summarises the findings of
fourteen studies which included at least some breast
cancers. No clear picture of ras expression emerges and
major differences between the findings of different
studies are hard to interpret. Some of these issues will
be addressed in the next subsections.
1.10.1 DNA: ras genes
Studies of ras genes have sought rearrangement,
amplification, mutation, rare alleles and allelic loss.
Biunno et al [9] examined all three ras genes in 65
carcinomas and found no rearrangements. One case only
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showed a fifty-fold c-Ha-ras amplification absent from
white blood cells of the same patient but this carcinoma
did not overexpress c-Ha-ras mRNA. Biunno et al sought
altered restriction enzyme cleavage fragment sizes which
could have disclosed mutations at position 12 of c-Ha-ras
and c-Ki-ras, and found none.
Transfection assays on the same cases were also negative.
Theillet et al [136] found no mutations of codon 12 of c-
Ha-ras and c-Ki-ras genes of 32 and 64 carcinomas
respectively, using similar analytic methods but not a
transfection assay. The contrast with colorectal
carcinoma is striking, for there a high incidence of
mutation, particularly at codon 12 of the c-Ki-ras gene,
has been documented, albeit by other techniques [11,40].
Some at least of this difference may reflect the
sensitivity of the methods used. Bos et al [11] probed
amplified DNA with oligomeric probes while Forrester et
al [40] used RNAase A mismatch cleavage analysis. These
methods may detect mutations that other methods would
not. Slight degradation of tumour DNA could negate
transfection assays especially for large genes such as c-
Ki-ras which has more than 45,000 base pairs. Codon-12
mutated c-Ha-ras genes were detected in two of 24
carcinomas by Spandidos [123] and in a cell line derived
from a breast "carcinosarcoma" [74] but the evidence
remains against a high frequency of transforming
mutations in breast cancer.
Krontiris et al [75] have suggested that rare alleles of
c-Ha-ras are more frequent in DNA from normal cells and
tumours in patients with diverse malignancies including
some breast cancers, and that the possession of such rare
alleles might reflect an inherited susceptibility to
cancer. Their study was based on a polymorphism of BamHI
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Study A B C D E F
Cancers 43 54 10 16 100 104
Controls 9 - CL - 100 WC
DNA analysis ---- + +
Allelic loss ....
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Table 1.5. Studies of ras expression in breast. Studies
F and G refer to the same 104 patients. Numbers refer
to benign cases except for study G (benign tissue from
the cancer cases). WC implies comparison with normal
white cells, CL with cultured cell lines. Y is
monoclonal antibody Y13-259, R is RAP-5. PC represents
polyclonal antisera. AA implies p21 or ras RNA elevated
at least 5 times in carcinomas relative to normal tissue
from the same or other cases; A, lesser but elevated
levels; > , detection without elevation; D, detection
without data for comparison with normal tissue. These are
the references: A=[27] B=[21] C=[132] D=[41] E=[82]




restriction fragment size reflecting variable tandem
reiteration of a 28-base-pair sequence adjacent to the c-
Ha-rasl gene itself [16]. There are four common alleles
designated A1, A2, A3, and A4. Experimental support for
Krontiris' hypothesis has only been forthcoming in the
study of breast carcinoma by Lidereau et al [79]. The
controls in this study were lymphocytes from people
without cancer themselves or in close relatives but it is
not clear that demographic comparability was assured. No
excess of rare alleles was found in one hundred
carcinomas from Edinburgh [82]. In that study placentae
from women delivering infants in Edinburgh were
appropriate controls. McGee's group in Oxford have come
to the same conclusion [85]. There is doubt, therefore,
whether rare ras alleles do relate to increased cancer
risk. The recent demonstration that a single nucleotide
substitution in the 4th intron of the T24/EJ Ha-ras
oncogene increases ras expression tenfold provides a
basis for believing that rare alleles could be important
[23] .
More definite is the finding of ras homozygosity in
carcinomas arising in patients heterozygous for ras in
lymphocytes, presumably due to the deletion of a larger
or smaller portion of the short arm of chromosome 11.
MacKay et al [82] and Theillet et al [136] found
comparable rates for the evolution of homozygosity in
heterozygotes, fourteen of sixty-five and fourteen of
fifty-one respectively. Lower rates have been reported
[9]. The significance of allelic loss is unclear.
According to Theillet et al [136] such loss is commoner
in oestrogen-receptor negative, high-grade tumours.
MacKay et al found the same relationship to receptor
status and that larger tumours were more likely to show
loss. The relatively frequent occurrence of a deletion
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on the short arm of chromosome 11, site of human c-Ha-
rasl. may reflect participation not by that gene itself
but by an adjacent anti-oncogene lost during the
evolution of breast carcinoma. Ras allelic loss in such
a case might mark the deletion. The Wilms tumour anti-
oncogene is located on the short arm of chromosome 11,
although there is no specific evidence linking this locus
with breast cancer.
1.10.2 RNA: ras transcription
If studies of ras genes have not yielded a coherent
picture, nor have those of RNA expression. Spandidos and
Wilkie [119] reported Ha-rasl mRNA expression in
carcinomas at levels 2.5 to fifteen times that in non¬
neoplastic parenchyma from the same cases, relative to
the same quantity of ribosomal RNA. The relative
contribution of epithelial and stromal cells in their
study cannot be assessed. Sixteen of twenty-two
carcinomas examined by Theillet et aJL [136] expressed
mRNA complementary to c-Ha-ras and not to c-Ki-ras, but
they did not relate the levels of expression found to
those in non-neoplastic breast parenchyma. Biunno et a_l
[9] compared twenty carcinomas with white blood cells
from the same patients and found elevated transcripts for
c-Ha-ras in 13, for c-Ki-ras in 6, and for c-N-ras in 3.
The findings of Whittaker et al [152] differ in that they
found abundant Ha-ras mRNA in only one of twenty-three
carcinomas while N-ras and Ki-ras transcripts were not
infrequent. These differences may reflect probe
specificity and stringency of hybridization and detailed




1.10.3 Protein: ras translation
Neither has a clear picture emerged of ras protein
expression in carcinomas. Different studies have used
monoclonal [64] and polyclonal [132] antibodies raised
against peptide fragments of p21 ras molecules, or
monoclonals against cells infected with Harvey murine
sarcoma virus [43]. Biochemical and immunocytochemical
studies have used different technigues so it is not
surprising that varied findings are reported. Nonetheless
some of the differences observed are hard to explain even
on this basis. Thus four immunocytochemical studies
[15,41,45,95] employing the same monoclonal antibodies
have reported guite divergent findings. Ohuchi et al
[95] used mouse monoclonal RAP-5, from the RAP series
generated by immunization with synthetic peptides
corresponding to amino acids 10-17 of normal and mutated
p21 ras [64]. They showed marked differences between
immunoreactivity of normal breast parenchyma, usual and
atypical hyperplasias, carcinoma in situ and invasive
carcinoma, with a marked trend towards increased
expression in the more abnormal epithelial elements.
They studied formalin-fixed paraffin-embedded tissues and
stated that an identical pattern of staining was obtained
on the same material with rat monoclonal Y13-259 [43].
Fromowitz et al recorded strong staining of carcinomas
with RAP-5 without staining of normal parenchyma [41].
But, also studying formalin-fixed paraffin-embedded
tissue, Ghosh et al [45] employed the same antibody and
could detect no differential immunoreactivity between
benign and frankly malignant tissues. A similar gulf
separates the results of Candlish et al [15], using rat
monoclonal Y13-259 on acetone-fixed cryostat sections,
who found a pattern similar to that seen by Ghosh et al
[45], from those of Ohuchi et al [95] using the same
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antibody on formalin-fixed paraffin-embedded tissue. At
least a major difference in technique exists in this
latter example. Otherwise differences in reactivity make
one suspect that different antibodies are being
described. Confusion in print between different anti-
p21-ras antibodies occurs; in the report by Horan Hand et
al [64], in which the RAP antibodies were originally
described, detection of p21 ras in paraffin sections is
reported with Furth's antibody 'YA6-259', which was not
among the eight reported by Furth and may be a confusion
of Y13-259 with one of the four YA6 series antibodies.
Another paper [54] imprecisely truncates Y13-259 to
'Y259' throughout.
Biochemical evidence from two studies using Western blots
with Y13-259 corroborates those immunocytochemical
studies which have suggested a large difference in p21
ras expression between benign and malignant breast
tissue. De Bortoli et al [27] found a fivefold or
greater elevation in p21 ras in 21 of 43 carcinomas
relative to benign breast tissue, and Clair et al [21]
found a comparable elevation in 21 of 54 carcinomas.
Overall, then, the evidence favours elevated expression
of a Ha-ras (probably non-mutated) gene in many breast
carcinomas.
1.11 Other oncogenes and breast carcinoma
Few studies have addressed other oncogenes and often
reports have been concerned with few cases. Thus in the
context of a much larger study Slamon et ad [117]
examined mRNA for a number of oncogenes and were able to
demonstrate transcripts of fes, fos, fms, myc. Ha- and K-
ras in at least three of four carcinomas, but abl, mvb
and src not so often. Biunno examined twenty cases for
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transcription of eight oncogenes relative to white blood
cells and found elevated fos and Ha-ras transcripts in 13
and 15 respectively. They also found c-myc amplification
in two of 45 carcinomas examined.
More recently, particular interest has centred on the
genes c-erbBl and c-erbB2. The former is now identified
with the epidermal growth factor receptor gene [140].
The latter has 50% sequence homology witn c-erbBl and is
thought to encode a receptor molecule for an as yet
uncharacterised ligand [110]. This gene has also been
independently discovered in humans and named HER-2 [24]
and v-erbB related gene [73] and appears to correspond to
rat neu gene [107]. EGF receptor is expressed in breast
carcinomas and may be expressed in greater concentration
in carcinomas with adverse prognostic features.
Amplification of c-erbB2 was first identified in a breast
cancer [73] and the same abnormality has been documented
in 15 of 86 carcinomas (17%) examined by Zhou et ad
[157], and in 2 of the series of 11 by Slamon [116].
Slamon has suggested that c-erbB2 amplification
correlates with an adverse prognosis and cautious support
for this comes from Zhou et al. who found amplification in
only one of twenty-one node-negative carcinomas but in
eight of thirty-seven node-positive cases. De Vijver et
al [141], Venter et al [143], and Gusterson et al [56]
showed c-erbB2 amplification associated with increased
expression of the encoded protein. The former study
contains no clear statement of numbers studied but only
two of ten carcinomas with lymph node metastases showed
positive staining for c-erbB2 protein in primary or node
deposits. A subseguent publication by this group [142]
confirmed the close correlation between c-erbB2
amplification and protein expression but did not show a
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relationship with relapse-free survival in a series of
187 patients of whom 27 had carcinomas in which c-erbB2
protein immunohistochemistry was positive. Venter et al
[143] showed amplification of the gene in 12 of 36
carcinomas. Amplification of c-erbB2 has been shown in a
minority of breast carcinomas and although the suggestion
that it is related to an adverse outlook is not yet
certain this gene and its product certainly merit the
attention they currently receive. No other oncogenes
show consistent patterns of involvement.
1.12 Approaches to oncogenes in the breast
We have seen from earlier discussion (1.1) that the
lesions which are thought to be precursors of breast
cancer arise in the terminal duct lobular units (TDLU).
As these structures are only one or two millimetres in
diameter, biochemical methods appropriate to invasive
cancers may not be applicable. In general the methods of
DNA, RNA and protein analysis reguire greater quantities
of tissue than are available. Amplification of DNA from
single tissue sections, by the polymerase chain reaction,
has recently been applied with impressive results, but
this method is competent to answer only certain questions
about known DNA sequences. Larger quantities of tissue
could be analysed but at the expense of precise knowledge
of what is being examined. Even if it were possible to
examine a representative histological preparation, the
heterogeneity of the tissue would remain a problem, as it
is unusual for a population of lobules all to show the
same abnormality. Widespread ductal carcinoma in. situ
(DCIS) is not uncommon but is an advanced lesion; the
morphological features of carcinoma are already fully
developed. Immunohisto-chemistry and in situ
hybridization preserve morphology and allow some
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assessment of biochemical activities within tissue.
Adaptations of these methods do allow some degree of
quantitation, which is likely to become a more routine
feature of such studies than at present, but there are
considerable technical problems.
In their studies of the sub-gross anatomy of breasts from
women with breast cancer and of random autopsy material,
Jensen and her colleagues showed that the number of
atypical lobules varies dramatically. Sometimes one or
two lesions are found, while in other cases there are
several hundred. In the latter it is not difficult to
obtain material for further study while in the former
chance plays a part. The method used by Jensen would have
limited utility for immunohistochemistry and in situ
hybridization studies because the whole breast is fixed.
However, Jensen et ajL proposed a related but simpler and
more flexible technique to obtain unfixed altered and
atypical units, by staining thin slices of tissue with
methylene blue in an ice-cold culture medium and
examining the fresh slices under the dissecting
microscope; tissue could be selected on the basis of
staining. Jensen used this method to obtain altered
lobules for experiments on the angiogenic response
obtained when these lobules were implanted in the
anterior chamber of the eye of the rabbit; and it has
been used to obtain morphologically normal lobules for
studies of thymidine labelling in normal breast [47].
Compared to the examination of cleared fixed tissue
stained with haematoxylin, this method has two
disadvantages. One is that the tissue is still viable
and excludes dye, thereby preventing appreciation of
morphological details. The other disadvanatage is that
what staining does occur is confined to the superficial
layers of the slice. These considerations
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notwithstanding, it was felt that this method offered the
best approach to obtaining altered and atypical parenchma
which could be examined by immunocytochemistry. The
selection of unfixed tissue would make it possible to use
cryostat sections with monoclonal antibodies such as the
the pan-ras reactive rat monoclonal Y13-259, which
recognises an epitope which does not survive formalin
fixation and paraffin embedding [153].
This thesis concentrates on expression of p21 ras.
Antibodies which work well in paraffin embedded tissue
have only recently become available for certain oncogene
products, for example c-erbB2. Antibodies which were
available, and were evaluated in preliminary work,
include anti-myc monoclonal antibodies 6E10 and 9E10,
antibodies directed against the epidermal growth factor
receptor, and monoclonal antibody Ki-67, directed against
a proliferation marker. None of these antibodies yielded
satisfactory immunostaining in paraffin embedded tissue,
whether fixed in conventional formaldehyde-based
fixatives, or PLP and PLPD.
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CHAPTER 2 SUPRAVITAL STAINING AND TISSUE SELECTION:
METHODS
2.1 Patients selected for study
The study population was composed of women with benign
and malignant breast conditions treated surgically at
Longmore Hospital, Edinburgh. All women with carcinomas
received surgery as part of primary therapy; women who
had received radiotherapy, chemotherapy, or surgical or
medical endocrine manipulations were excluded. Most
carcinomas were treated by mastectomy or wide local
excision. A few wedge biopsies of advanced carcinomas
were included. Cases were selected without defined age
limits but there was a bias towards women in their fourth
and fifth decades in whom atypical parenchymal lesions
were more likely to be present [150]. Some needle
localization biopsies were included.
2.2 Collection of tissue
Some benign biopsies were collected unfixed from the
operating theatre. Most biopsies and mastectomies from
malignant cases were brought unfixed to the department.
Almost all cases included in the present study were
examined by the author, sectioned, and tissue chosen for
diagnosis and other procedures as detailed below.
Pathological reporting was supervised by Dr. T.J.
Anderson. When particularly fresh tissue was wanted
specimen examination and sampling were done at Longmore
Hospital as soon as the specimen was available in
theatre. In general tissue slicing was performed within




The method of Buhring and Jensen was followed [13].
Fresh tissue was sliced into sheets 3-4mm thick using
disposable dermatome blades on a perspex jig. Blocks for
conventional histology were selected and remaining tissue
immersed in ice-cold nutrient medium or Ringer's solution
containing methylene blue with periodic agitation until
staining was strong enough to permit appreciation of
parenchymal architecture.
2.4 Examination and microdissection
Stained tissue was examined under a Leitz dissecting
microscope with a long operating distance and zoom
magnification x6 to x50. Areas of interest selected for
further examination were either dissected out with
ophthalmic scissors and forceps, with which single
lobules or stromal strips bearing several lobules were
dissected free, or larger, more conventional blocks were
selected.
2.5 Cryostat sectioning
Microdissection yielded l-5mm tissue fragments which were
placed in ice-cold nutrient medium or Ringer's solution.
When collection was complete, they were floated in OCT
embedding medium on a cryostat chuck as a close-packed
group in the same plane, and frozen with solid carbon
dioxide. A covering of further OCT put on just before
complete freezing ensured good support round tissues and
facilitated sectioning. 4-5 micron sections collected on




2.6 Fixation of tissues
2.6.1 Composition of fixatives
Almost all tissues were fixed in one of four fixatives.
These were Carson's solution [17], which is a buffered
formaldehyde-based fixative, periodate-lysine-
paraformaldehyde (PLP)[89], its dichromate derivative
(PLPD)[63], and acetone. Carson's fixative is our
routine fixative for diagnostic paraffin histology and
was used for that purpose. Acetone was used initially as
a fixative for cryostat sections as it gives good
antigenic preservation although morphological
preservation is poor. PLP and PLPD were used in an
attempt to combine good antigenic and morphological
preservation in paraffin embedded tissues. Details of
the composition of these fixatives are given in chapter
9.
PLP and PLPD were chosen because published data indicated
that these fixatives preserved lymphoid antigens which
did not survive well in conventionally fixed paraffin-
embedded tissue [63]. Determined attempts were made to
exploit Carson's fixed material as success would have
given access to a considerable body of archival material.
Pre-digestion with pepsin and trypsin for a variety of
times (1-24 minutes) and detection systems (including ABC
and IGS) were explored unsuccessfully. In addition to
PLP and PLPD, half-strength PLP containing 1 per cent
rather than two per cent paraformaldehyde gave excellent
Y13-259 immunoreactivity but poor morphology, for which




After air-drying for 30 minutes, cryostat sections were
fixed by immersion in acetone for 10 minutes at room
temperature, air-dried and stored in sealed boxes at -70C
until needed.
3mm tissue blocks in cassettes were fixed by immersion in
freshly prepared PLP and PLPD pre-cooled on ice.
Fixation was continued for 24-32 hours in a refrigerator
at a checked temperature of 4C. Similar blocks for
diagnostic histology were fixed in Carson's fixative for
16-24 hours at room temperature.
Fixation time was determined by practical considerations.
Tissues were put into fixative during the day (0900-
1700hrs) and washing started at 1700hrs next day. This
synchronised blocks for the next processing stage.
Longer fixation times up to 72hrs had no adverse effect
on immunoreactivity.
2.7 Tissue washing
Blocks fixed in PLP and PLPD were washed overnight (16
hours) in running tap water (average temperature 18C) to
remove residual dichromate which can react with alcohol
during processing to form an insoluble pigment. PLP-
fixed blocks were washed similarly in order to eliminate
major processing differences between PLP and PLPD fixed





Tissues fixed in PLP and PLPD were processed at room
temperature (20-24C) on a Histokinette. Dehydration
through graded alcohols was followed by clearing in
chloroform and xylene followed by impregnation with a
paraffin wax (Raymond Lamb) melting at 56C. Measured
temperature of the wax bath was 58-60C and blocks were
embedded in the same wax.
2.9 Preparation of paraffin sections
All sections were cut on Leitz microtomes at 4um.
Initial sections stained with Meyer's heamatoxylin and
eosin were assessed to select blocks for
immunohistochemistry. Sections from these selected
blocks were cut, mounted on gelatin-coated slides, dried
at 56C, and stored at room temperature before use.
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CHAPTER 3 SUPRAVITAL STAINING AND TISSUE SELECTION:
RESULTS
3.1 Supravital staining
Examination of supravitally stained unfixed breast tissue
with the dissecting microscope was rewarding in several
ways. Unfixed tissue retained its natural texture, which
was informative. Small lesions were palpable and diffuse
alterations invisible to the eye could be appreciated by
touch in a manner impossible in rigid, leathery fixed
tissue. Occasionally diffuse infiltration by lobular
invasive carcinoma was suspected in tissue which looked
normal. Even unstained tissue gave some idea of the
number and distribution of lobular units was apparent,
because the specialized myxoid stromal tissue surrounding
parenchymal units was translucent and appeared darker
than the white, opague, collagenous extralobular stroma.
A property of viable tissue is its ability to exclude
vital dyes, and breast tissue was no exception.
Parenchymal elements showed little tendency to stain with
methylene blue. Colour contrast was subtle and could be
difficult to appreciate. Illuminating the tissue through
an orange filter increased contrast but the effect was
weak by comparison with methylene blue staining of fixed
tissue which took up the stain strongly. If the plane of
section passed through an unfixed parenchymal unit, the
cut surface took up the dye more than if the plane of
section was tangential to a unit which retained its
integrity.
Some parenchymal alterations were characteristic under
the dissecting microscope. Normal lobules could usually
be appreciated because they formed a dominant population,
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and occasionally the epithelium took up enough dye to
make clear that there was no abnormal cellularity. At
the other extreme, the cell groups of invasive carcinoma
(figure 3.1) sometimes took up dye more readily than
benign epithelium and revealed a characteristic
streaming, infiltrative pattern, often extending between
adipocytes. It was almost always possible to be certain
when dealing with invasive carcinoma. Lesions such as
sclerosing adenosis, which might have simulated an
infiltrative pattern, were usually distinguishable by an
organoid nodular pattern. The elastotic centres of
radial scars and complex sclerosing lesions, so
characteristic histologically, were also prominent under
the dissecting microscope, having an ivory hue quite
distinct from white collagen. Dye uptake revealed the
radial parenchymal distribution while the absence of
characteristic streaming distinguished larger lesions
from carcinoma. Cysts were conspicuous when larger than
one or two millimetres in diameter. Phagocytic cells in
lymphatics were an exception to the general reluctance of
cells to absorb dye. Lymphatic networks around
parenchymal units were often outlined by chains of
intensely stained cells, presumably macrophages. This
property was useful on occasion as it sometimes revealed
the distribution of non-staining epithelial elements
within a unit. Red cells in capillaries did not take up
dye.
Other parenchymal changes were inapparent or
inconspicuous in supravitally stained tissues. The
subgross studies of Wellings and Jensen showed that a
variety of different cellular processes affecting lobules
were attended by similar changes of overall form. Thus
distension and coalescence of ductules could be
associated with cyst formation, epithelial hyperplasia of
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Figure 3.1. Supravitally stained breast tissue showing
invasive carcinoma of no special type. The infiltrating
pattern is subtle but almost diagnostic. x60.
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usual type, atypical hyperplasias of ductal or lobular
type, and carcinoma in situ. In supravitally stained
tissue these could all appear very similar although
distinctive features were sometimes found. Ductal
carcinoma in situ of comedonecrotic type was
characterised by an abnormally thick epithelial lining
with opague white-to-yellow central necrosis (figure
3.2). Duct ectasia could look similar but lacked thick
epithelium and the inspissated luminal content was less
solid than the necrotic material in DCIS. Lobular
carcinoma in situ was sometimes distinguished by
distention of lobular units (figure 3.3) but if
distention was absent, as often in atypical lobular
hyperplasia, such units were very difficult to tell from
normal.
3.2 Tissue selection
The initial approach to tissue selection for further
study was microdissection. This was time consuming and
yielded relatively few lesions. Lack of specificity was
a disadvantage. Freguently an interesting-looking,
potentially hyperplastic lobule turned out to be merely a
small cluster of interconnected apocrine cysts. This
sometimes became obvious when one of the cysts was
punctured during dissection and the group collapsed.
When it became apparent that good immunocytochemistry
could be performed on tissues fixed in PLP or PLPD and
embedded in paraffin, the collection strategy was
changed. Supravital staining was continued, but instead
of selecting individual units for study, larger areas of
tissue were selected to include all identifiable tissue
changes and 2-12 tissue blocks per case were selected for
fixation and paraffin embedding. The final selection of
areas for immunohistochemistry could be based on
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Figure 3.2. Supravitally stained breast tissue showing
ductal carcinoma in situ. Thickened epithelium and
opague necrotic material in the lumen are typical. xlO.
Figure 3.3. Supravitally stained breast tissue showing a
lobule with ductules expanded by lobular carcinoma in
situ. This expansion is the only clue to the




haematoxylin and eosin stained sections of these blocks,
with greatly improved precision over supravital staining
alone. The quality of histological preservation is
demonstrated in the next section, which also serves to
illustrate important morphological changes in breast
parenchyma, discussed in the introduction in relation to
cancer risk.
3.3 Histology
PLP and PLPD both gave satisfactory morphological
preservation of breast parenchyma for critical assessment
of histology. The atlas of lesions which follows
(figures 3.4-3.13) is confined to material fixed in PLPD,
which was the fixative used for immunohistochemical
assessment, and serves to illustrate the morphological
groupings used in these studies, which have been referred
to in the introduction, and to illustrate the good
quality of the histology obtained. All photographs are




Figure 3.4. Normal lobule. The terminal duct enters the
lobule at the 11 o'clock position. x40
Figure 3.5. Mild hyperplasia of usual type (ductal).
Some parenchymal units are expanded, with papillary




Figure 3.6. Florid hyperplasia of usual type (ductal).
The enlarged central unit is filled by a heterogeneous
population of cells with small slit-like spaces.
Cytological features are benign. x40
Figure 3.7. Atypical ductal hyperplasia: Cellular
monotony with mild cytological atypia and punched-out





Figure 3.8. Ductal carcinoma in situ: Cribriform type.
Contrast with figure 3.13. The monotonous cellular
population and structural uniformity identify this as
DCIS. xlOO
Figure 3.9. Atypical lobular hyperplasia. Normal
epithelium infiltrated by small atypical cells with pale
cytolasm and intracytoplasmic lumina. Residual normal
epithelium identifies this as ALH. xlOO
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Figure 3.10. Ductal involvement by cells of ALH.
Attenuated normal epithelium is stretched over groups of
ALH cells in which intracytoplasmic lumina are obvious.
xlOO
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Figure 3.11. Lobular carcinoma in situ. Characteristic
atypical cells occupy the entire lobular unit and are
present in the terminal duct (lower left), in which there




Figure 3.12. Invasive carcinoma: No special type.
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Figure 3.13. Invasive carcinoma: Lobular type. Single
files of small malignant cells stream through the tissue.
Intracytoplasmic lumina are present in some cells. xlOO
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CHAPTER 4 IMMUNOCYTOCHEMISTRY FOR LIGHT MICROSCOPY:
METHODS
4.1 CHL cells and the cell line FH05T1
FH05T1 and CHL cells provided positive and negative
controls for immunochemistry. They have been described by
Spandidos and Wilkie [122]. Briefly, the FH05T1 cell
line was derived by transfection of an early passage
Chinese hamster lung fibroblast strain (designated CHL)
with the plasmid pH05Tl, which contains the mutationally
activated human T24 Harvey-ras oncogene ligated to viral
enhancing seguences.
4.2 Conditions of culture
FH05T1 and CHL cells were maintained in Dulbecco's
modification of minimum Eagle's medium, containing 10 per
cent newborn calf serum, penicillin, and streptomycin.
Cell suspensions were prepared from monolayers by
treatment with 0.02 per cent EDTA and 0.1 per cent
trypsin in Dulbecco's phosphate buffered saline (PBS) and
washing in PBS.
4.3 FH05T1 experimental tumours
Female CBA mice about 6 weeks old, immune-deprived by
thymectomy, whole-body irradiation and treatment with
cytosine arabinoside, were obtained from the colony
prepared by Dr CM Steel, MRC Human Genetics Unit,
Edinburgh. Subcutaneous injection of FH05T1 cells
engenders malignant fibroblastic tumours as described by
Wyllie et al [156]. Samples of such tumours sliced to 3-
5mm were placed immediately in PLPD. Fixation and
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subsequent processing were as described for human
tissues.
4.4 Preparation of cell cultures for microscopy
4.4.1 Cytospin preparations and smears
Twenty microlitres of suspensions containing five million
FH05T1 or CHL cells per ml of culture medium were used to
prepare air-dried smears on plain slides subsequently
fixed in acetone for 10 minutes. PLP and PLPD fixation
of such preparations detached the cells. Cytospin
preparations on plain or gelatin-coated glass slides were
fixed in acetone for control purposes. Smears and
cytospins were used at once or stored at -70C in sealed
containers.
4.4.2 Agar-paraffin cell blocks
The most useful control materials (after the FH05T1
tumours) were prepared by suspending briefly fixed CHL
and FH05T1 cells in low-melting point agarose (FML
Bioproducts) and post-fixing before processing to
paraffin. Approximately five million cells were fixed
for 15 minutes at 4C, washed in PBS, and resuspended in
0.5ml of 2 per cent agarose in PBS at 40C. After
setting, this pellet was post-fixed for up to 24h, washed
in PBS, and processed to paraffin. Fixatives included
PLP, PLPD, half-strength PLP, buffered 4 per cent
formaldehyde and 2 per cent glutaraldehyde. Sections
were cut as for tissues. These agar-paraffin cell blocks
had the advantage of yielding many control sections fixed
and processed like tissues.
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4.5 Fixatives for control cells and tissues.
As mentioned briefly above, a variety of fixatives were
used in the fixation of control cells and tissues. To
those mentioned in the last paragraph Carson's fixative
[17] may be added. These various fixatives were used for
a variety of purposes and are described in more detail
where relevant.
4.6 Monoclonal antibody Y13-259
The hybridoma was a gift from Dr Demetrios Spandidos.
This well-characterised pan-ras antibody recognises an
epitope encoded by a conserved region of the gene and
represented in the proteins encoded by Ha-ras, Ki-ras.
and N-ras. Activation of the oncogene is not associated
with mutation affecting the amino acids recognised by
this antibody. There is no specificity, therefore, for
mutated or non-mutated forms of ras protein; both are
recognised. Antibody was purified by ammonium sulphate
precipitation from serum-free culture supernatant and
dialysed exhaustively against PBS.
4.7 Storage of antibody Y13-259
Aliquots of 3OOul of concentrated dialyzed culture
supernatant were stored at -70C in 1ml Eppendorf tubes.
For use, the aliquots were thawed and stored at 4C with
sodium azide (0.1 per cent w/v) added to prevent
infection. To confirm that sodium azide as a preservative
did not interfere with immunostaining the results of
staining with the primary antibody at four dilutions
(1:20, 1:40, 1:80 and 1:160) were compared with and
without 0.1 or 0.01 per cent sodium azide. These
concentrations of azide exceeded the concentration
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obtained when primary antibody preserved with azide at
0.1 per cent was diluted 1:50, which was the usual
working dilution. It was determined that azide
preservation had no harmful effects on immunostaining.
Nor did preserved primary antibody show any deterioration
of staining over at least three months, judged on
positive control material. This method proved more
satisfactory than storage of multiple small frozen
aliguots, which gave inconstant immunostaining.
4.8 ABC immunostaining
4.8.1 ABC immunostaining procedures
Avidin-biotin complex immunostaining was selected for its
sensitivity and specificity. The protocol is given in
chapter 9. Initial immunostaining runs with cryostat
sections fixed in acetone were poorly reproducible on
positive controls (cryostat sections of FH05T1 tumours
from mice or smears or cytospin preparations of cultured
FH05T1 cells). Variations in technique were tried to
improve sensitivity and consistency but changing buffer
preparations, batch and lot of second and third layer
reagents (biotinylated goat anti-rat antibody and
streptavidin-biotin-peroxidase complex), blocking serum,
diaminobenzidine, hydrogen peroxide, xylene and alcohols
did not help.
An alternative to ABC immunostaining that might be more
sensitive was sought, and immunogold-silver (IGS)
staining methods were considered [62] in conjunction with
specialised fixatives periodate-lysine-paraformaldehyde
(PLP) and its dichromate derivative (PLPD). Published
data show that these fixatives preserve many antigens
which do not survive conventional formaldehyde fixation
- 72 -
Chapter 4
and paraffin embedding, especially if sensitive IGS
staining methods are used [63]. As cryostat section
morphology was poor, the combination of PLP or PLPD
fixation, paraffin embedding and IGS staining offered
solutions to several difficulties. In practice,
consistent immunostaining was achieved when storage of
hybridoma culture supernatant preserved with sodium azide
at 4C was adopted. It is presumed that the previous
variation in staining related to storage of primary
antibody as small frozen aliguots. Avidin-biotin complex
immunostaining was retained but the good morphology and
immunoreactivity of PLP and PLPD fixed paraffin-embedded
tissue were reasons for their use in preference to
cryostat sections.
Various dilutions of Y13-259 (1:10, 1:20, 1:30, 1:40,
1:50, 1:60, 1:80, 1:100, 1:120, 1:160, 1:200, 1:400,
1:800, 1:1600, 1:3200) were used on breast and control
tissues to establish optimal conditions. It was found
that the dilution subsequently employed (1:50,
corresponding to 50 jjg/ml) gave most consistently
reproducible immunostaining of positive control material
(FH05T1 cells and tumours) and breast tissue, with
acceptably low background.
It was noted informally in the course of this
optimization process that as greater dilutions of Y13-259
were used, immunostaining of DCIS and invasive carcinoma
decreased by equivalent amounts with each increase in




4.8.2 ABC immunostaining specificity
Positive and negative controls ensured sensitivity and
specificity of immunostaining. The FH05T1 cell line as
cultured cells and as tumour in immune-deprived mice was
the cornerstone positive control (figures 4.1, 4.2).
Every run included positive control slides, often more
than one, to provide checks on inter- and intra-run
variability. A variety of negative controls were
included. Omission of primary antibody, replacing it
with buffer plus blocking serum alone, was a standard
control included for every slide examined. This allowed
appreciation of endogenous peroxidase activity and
avoided confusion with natural or artefactual pigments.
A second control used in some runs was to replace Y13-259
with non-immune rat polyclonal IgG at the same
concentration. If such antibody is used without
modification, a complex immunostaining pattern is seen in
human material (figure 4.3). This is not surprising in
view of the complex mixture of antibodies present. A
more useful control was obtained by absorbing rat
polyclonal immunoglobulin with acetone-treated human
liver powder [92]. This removes cross-reacting
antibodies and such absorption essentially abolished
immunostaining (figure 4.4), which implied that non¬
specific reactions with the Fc portion of the
immunoglobulin molecule were unimportant. Figure 4.5
shows the same carcinoma immunostained with Y13-259.
A third negative control, of a different type, was
provided by CHL cells which express p21 ras at levels 30-
60 times less than FH05T1 cells [156]. Immunostaining of
these cells with Y13-259 was always negative (figure
4.6). During routine staining runs, the only positive
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Figure 4.1. PLPD-fixed FH05T1 cells growing as tumour in
immune-deprived mice. Y13-259 5(Dpg/ml, ABC detection.
x250
t-
Figure 4.2. PLPD-fixed cultured FH05T1 cells embedded in
agar and paraffin. Y13-259 50jig/ml, ABC detection. x400
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Figure 4.3. PLPD-fixed breast carcinoma. Unabsorbed
non-immune rat IgG, 50pg/ml, with ABC detection gave
pronounced non-specific immunoreactivity. x250
Figure 4.4. The same PLPD-fixed breast carcinoma. Non¬
specific immunostaining abolished by pre-absorbtion with
acetone-treated human liver powder. Absorbed non-immune
rat IgG 50j-ig/ml, ABC detection. x250
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Figure 4.5. The same PLPD-fixed breast carcinoma. Y13-
259 5Ctyag/ml, ABC detection. There is strong specific
immunostaining. x250
Figure 4.6. PLPD-fixed cultured CHL cells embedded





control always included was a section of PLPD-fixed
paraffin-embedded FH05T1 tumour. Negative controls
omitting the primary antibody were processed for every
section in every run. Positive control breast sections
were not considered necessary in every run. In a run of
ten cases there was always positive immunostaining in
some or all of the test sections, in particular of
elements such as vascular smooth muscle. Experience
showed that if FH05T1 controls showed positive
immunostaining, then test sections always did so too.
The relationship between fixation and the level and
subcellular distribution of p21 ras was investigated in
several ways. Animal FH05T1 tumours were fixed in PLP or
PLPD immediately and after a 10 minute or 1 hour delay,
which had no effect on the intensity or distribution of
immunostaining. With human tissues, the time between
surgery and fixation was always minimised, but in four
cases trucut biopsy cores of large malignant tumours were
obtained and placed in PLPD within one or two seconds of
removal from the breast. These four neoplasms showed
typical cytoplasmic rather than membrane staining.
4.9 Measurement of Y13-259 concentration
The concentration of immunoglobulin in purified culture
supernatant was measured by Mancini single radial
immunodiffusion [68]. Procedural details are given in
the chapter 9 but the principle is that antigen put into
wells bored in an agar gel containing a known antibody
dilution will diffuse from the well until an
immunoprecipitin halo forms when antigen-antibody
equivalence is reached. Mancini showed that the diameter
of the halo is proportional to antigen concentration.
Polyclonal goat anti-rat IgG (Sigma) diluted 1:10 and
- 78 -
Chapter 4
1:20 was used to precipitate Y13-259 from culture
supernatant diluted 1:5-1:80 and immunoprecipitation ring
diameters were standardized against dilutions of rat IgG
10 mg/ml (Sigma). At least 48 hours were allowed for
equilibration before gels were stained with Kenacid Blue
R to enhance rings which were measured to the nearest
0.1mm with a magnifying eyepiece micrometer. Figure 4.7
shows the rings. Figure 4.8 represents one experiment
comparing ring diameters for dilutions of Y13-259 culture
supernatant (unknown) and of rat IgG, lOmg/ml standard.
The lines fitted by least squares are parallel and show
the standard concentration was four times that of Y13-
259, which was therefore 2.5mg/ml. Identical results
were obtained on repeating the test.
To see whether absorption of non-immune rat
immunoglobulin with acetone-treated human liver powder
materially reduced the concentration of immunoglobulin,
Mancini gels were set up using the same dilutions of
unabsorbed and absorbed immunoglobulin. The result is
depicted in figure 4.9 and no difference in
immunoglobulin concentration can be detected.
4.10 Immunogold-silver staining
Immunogold staining has developed since the 1970s and
silver enhancement widens its applicability. Many
different proteins may be adsorbed onto colloidal gold
and methods exist for the preparation of colloidal
particles as small as 3nm. In various sizes these are
excellent probes for electron microscopy. For light
microscopy deposition of metallic silver on gold nuclei
by 'physical development' confers signal amplification up
to several orders of
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Figure 4.7. Immunoprecipitation rings in Mancini gel
intensified with Kenacid Blue R. x3
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Figure 4.8. Ring diameters in Mancini gels for rat IgG
standard (known concentration) and Y13-259 (unknown) for
different dilutions. Dilutions of rat IgG four times






Figure 4.9. Ring diameters in Mancini gels for non-immune
rat IgG before and after absorbtion with acetone-treated




magnitude permitting detection of scarce antigens or use
of high dilutions of primary antibody in immunochemical
procedures. These properties suggested IGS staining when
it was proving difficult to get good ABC immunostaining
with Y13-259. In practice, although IGS staining worked
well (figure 4.10), once the problems with ABC
immunostaining had been solved, it offered no routine
advantage and was not therefore used for most light
microscopic work but has been used for electron
microscopy.
Several authors state that maximum sensitivity of IGS
staining requires pre-treatment of sections with Lugol's
iodine solution for 5 minutes [62,63,124]. The use of
Lugol's iodine was investigated and it was shown that
exposure of sections to Lugol's iodine before the primary
antibody was applied invariably abolished immunostaining
whether applied for 5 seconds, 5 minutes or intermediate
times. This was true for ABC detection and IGS staining.
Iodine was clearly inimical to the epitope recognised by
Y13-259 and its use was abandoned.
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Figure 4.10. PLPD-fixed FH05T1 cells growing as tumour




CHAPTER 5 IMMUNOCYTOCHEMISTRY FOR LIGHT MICROSCOPY:
RESULTS
5.1 Results: Control tissue
In this chapter qualitative accounts of Y13-259
immunostaining in controls and breast are followed by a
description of the development and validation of a
semiquantitative scoring system incorporating extent and
intensity of immunostaining. Results for different cell
populations of normal and abnormal breast are presented
in terms of this score, which permitted statistical
testing of staining differences between populations.
Discussion of results follows in chapter 8.
5.1.1 ABC Immunostaining
Once methodological problems were resolved reliable
immunostaining of FH05T1 cells, whether as smears,
cytospins, agar-paraffin blocks, or growing as
experimental tumours was attained. Immunostaining was
predominantly related to plasma membrane, especially in
experimental tumours (figures 4.1, 4.10). Cells
harvested from culture showed membrane but also some
cytoplasmic staining. Omission of primary antibody or
replacement with absorbed non-immune rat immunoglobulin
gave no staining.
Scoring of immunostaining was confined to runs in which
positive controls showed strong positive staining, and
the range of appearances of the test sections were
considered to be representative on the basis of previous
experience. "Positive" staining was regarded as the
presence of an unequivocal signal; very weak signals were
not considered acceptable evidence of immunostaining,
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although in the scoring process borderline positivity was
scored appropriately (+/-). Vascular smooth muscle,
being consistently positive in test sections, were useful
internal positive controls.
PLPD gave better preservation of Y13-259 immunoreactivity
in agar-paraffin blocks than PLP. This was probably a
consequence of the lower aldehyde concentration in PLPD
rather than any positive effect of the dichromate,
because half-strength PLP, which has exactly the same
composition as PLPD without dichromate, gives if anything
better immunoreactivity than PLPD, but poorer morphology.
5.1.2 Immunogold-silver staining
Immunogold-silver staining gave similar results to ABC
detection. Using the first version of Janssen's
'IntenSE' silver enhancement kit (see chapter 9 for
details) it was possible with repeated cycles of
enhancement to attain very strong signals (figure 4.10)
but for routine use the more cumbersome procedure had no
advantage, nor was the ratio of signal to background any
better.
5.2 Results: Breast Tissue
5.2.1 General description
Most breast tissue showed some immunoreactivity with
monoclonal antibody Y13-259. In general, tissues fixed
in PLPD showed stronger immunoreactivity than tissues
fixed in PLP, but with slightly stronger background
staining. Tissues fixed in Carson's fixative (a buffered
formaldehyde solution) showed minimal or no
immunoreactivity. As some authors have found that Y13-
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259 immunoreactivity survives in formaldehyde-fixed
paraffin-embedded tissues [95], this was explored by
comparing the results of immunostaining of separate
portions of three carcinomas each fixed in PLP, PLPD and
Carson's fixative and processed together to eliminate
variation in post-fixation conditions. Superiority of PLP
and PLPD was obvious. Figures 5.1 and 5.2 illustrate
immunostaining in PLPD and Carson's fixed tissue. As
morphological preservation was perhaps slightly better
with PLPD, this fixative was favoured for routine
assessment. Among non-neoplastic tissues, some elements
consistently showed immunostaining. Most notable were
the smooth muscle in small muscular blood vessels,
myoepithelial cells, and cells showing apocrine
metaplasia. Epithelium of large and small ducts showed
heterogeneity of staining within and between cases. In
general, hyperplastic epithelium stained more strongly
than non-hyperplastic epithelium. Other stromal elements
usually showed little staining. In general, most cancers
(both invasive and non-invasive) showed strong
immunostaining and were generally stronger in their
staining than adjacent benign epithelial elements.
Atypical proliferations appeared to stain with
intermediate intensity. Strong membrane staining was
rare in human breast tissue, including carcinomas.
Figure 5.3 shows an exception: In this lobular carcinoma
in situ membrane staining was obvious, although there was
also cytoplasmic staining. Cf. figures 4.5 and 5.1.
To investigate these relationships further a method of
codifying staining was necessary, which would have a
semi-quantitative relationship to p21 ras expression if




Figure 5.1. PLPD-fixed paraffin-embedded breast
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Figure 5.2. Carson's-fixed paraffin-embedded breast




Figure 5.3. PLPD-fixed lobular carcinoma in situ showing
membrane staining. Y13-259 5(Dpg/ml, ABC detection. x400
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5.2.2 Quantification of staining
Immunocytochemistry presents problems for quantitation,
chiefly because the relationship between intensity of
staining and quantity of antigen is non-linear, rising
steeply with increasing antigen at low concentrations of
antigen but flattening off and scarcely rising with large
increases when the antigen is more abundant [52].
Nonetheless the same source shows that a relationship
does exist and given reasonably reproducible positive
controls from run to run a scoring system is worthwhile.
A four point score for intensity of staining was adopted,
as follows. No staining, score 0; weak, equivocal
staining (+/-), score 1; definite positivity (+), score
2; strong positivity (++), score 3. The other chief
variable is the percentage of cells immunostaining within
a given population. As staining heterogeneity was
marked, it seemed proper to incorporate this into a
scoring system. This was estimated by determining for a
particular element whether positivity was present within
0-25 per cent, 25-50 per cent, 50-75 per cent, or 75-100
per cent of cells. These were scored as 1,2,3, or 4 in
that order. These two scores, representing extent and
intensity, were combined as shown in table 5.1. No
staining scored 0. Weak, equivocal staining of less than
50 per cent of cells scored 1, greater than 50 per cent
scored 2. The scores for positive or strongly positive
staining were added to the extent score as shown in table
5.1. Thus the overall score was from 0 to 7 (no
staining, to more than 75 per cent of cells strongly
positive).
Elements scored included normal epithelium and stroma,
hyperplastic, atypical, and neoplastic epithelium and
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reliability and validity of scoring, forty-two cases were
scored twice, on separate occasions and without reference
to the previous score on the second occasion. This
allowed scores to be compared for 311 separate epithelial
and stromal elements. The result of this exercise is
presented in figure 5.4. The areas of sguares are
proportional to the number of paired scores in each cell
of the matrix. Complete concordance is represented by
sguares on the diagonal from lower left to upper right,
ie tied pairs. The smallest sguares represent single
pairs of scores. Overall agreement is good (Spearman
rank correlation coefficient 0.75, p<0.001). There is no
evidence of systematic bias in either direction between
the two comparisons (Wilcoxon matched-pairs signed-ranks
test) .
A few outlying single points in figure 5.4 represent poor
reproducibility of scoring. It is not unusual to see
variation in the intensity of immunostaining within a
single section, particularly near the edge where staining
intensity may be stronger, if evaporation concentrates
reagents, or weaker, if reagents are not spread uniformly
over the section. Considerable care was taken during
immunostaining to avoid these effects, but they are
difficult always to eliminate, and it is not always easy
to be certain which area of staining of a section is
truly representative. It is considered that the small
number of markedly discrepant points represent different
interpretation of the correct area to score on separate
occasions.
A second exercise compared scores for 155 elements
present in a further 26 cases for which tissue fixed in
PLP and PLPD was available. PLP and PLPD fixed tissues
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Figure 5.4. Comparison of repeated scoring of
immunostaining for 311 paired observations from 42 cases,
Area of squares is proportional to number of pairs in















Figure 5.5. Comparison of scoring for 155 paired
observations from 26 cases fixed in PLP and PLPD.
Construction as figure 5.10.
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Results are presented in figure 5.5. Again correlation
is good (Spearman rank correlation coefficient 0.67,
p<0.001) . In this case there is a systematic bias,
scores for PLPD fixed tissue tending to be higher than
those for tissues fixed in PLP (70 ties, 53 with PLPD
score greater than PLP score, 32 with PLP score greater
than PLPD score; p=0.02). This confirms the subjective
impression that antigenic preservation is better with
PLPD.
These comparisons validated the scoring system and it was
adopted for case assessment. This assessment was
recorded on the pro-forma in table 5.2 and completed for
all cases before data analysis.
It should be noted that the data in figure 5.5, comparing
immunostaining of different blocks from the same cases,
fixed in PLP and PLPD, allow one to assess the
variability of p21 ras immunostaining from block to
block, and from staining batch to staining batch. As the
variability observed was no greater than that observed on
repeated scoring of the same blocks (figure 5.4), it was
considered that variability from these sources was not
significant.
5.2.3 Results of guantification
It was felt that normal epithelium was the proper
standard with which to compare pathological epithelial
alterations. The first analysis was to determine whether
expression of p21 ras depended upon site in the duct
tree, separating large ducts, small ducts and TDLU.
These data are presented in figure 5.6 (upper three
boxes). Within each box scores are indicated on the x
axis while the percentage of cases with that score is
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given on the y axis. It will be seen that the patterns
are very similar for all three boxes, suggesting no
topographic correlation with p21 ras expression. If
comparable data for myoepithelial cells are examined, a
different but also internally consistent pattern is seen.
Larger numbers of cases show stronger staining than for
the epithelial cells. To analyse these differences the
Kolmorogov-Smirnov two-sample test was selected. This
non-parametric test requires no assumptions about data
distribution. To perform the test cumulative frequency
tables are compiled for the two samples and the maximum
unsigned difference between the two cumulative
frequencies is determined. This constitutes the test
statistic, D. The null hypothesis is that there is no
difference between the two samples and the test assesses
the probability of a D value as great as that observed.
Tabulated values for various sample sizes are available
[118].
The Kolmogorov-Smirnov test suggests a graphical
representation of the data already presented in figure
5.6, which makes similarities and differences more
apparent. This is to plot the cumulative proportion of
cases associated with each score rather than the
proportion for that score only. Clearly, for any pair of
curves, the one on the left represents a set of
observations with generally lower scores than the one on
the right. Figure 5.7 presents the data for epithelial
and myoepithelial cells of large ducts (the data in the
two left-hand boxes in figure 5.6). The vertical line
indicates D, the greatest difference in cumulative
frequency, and for the numbers here, this difference is
highly significant (p<0.001), confirming the visual
impression that myoepithelial cells stain more intensely.
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Figure 5.6. Frequency histograms of scores for Y13-259
ABC immunostaining. Normal epithelial and myoepithelial
cells in large ducts (148 cases), extra-lobular terminal









"I 1 1 1 r
0 1 2 3 4 5 6
Score
Figure 5.7. Cumulative frequency curves of scores for
Y13-259 ABC immunostaining. Normal epithelial and
myoepithelial cells of large ducts. D represents the
greatest difference between the two curves and
constitutes the Kolmogorov-Smirnov test statistic.
- 96 -
Chapter 5
added, but rather than give all points, the areas within
which the lines for epithelial and myoepithelial cells
lie are indicated. It will be seen that the curves for
epithelial cells lie within narrow limits as do those for
myoepithelial cells. Testing shows no differences
between epithelial cells or myoepithelial cells at
different loci in the duct tree but highly significant
differences between p21 ras expression of epithelial and
myoepithelial cells at all levels.
In practical terms it was obvious that it did not matter
which ducts were chosen to represent normal epithelium.
Lobular ductules were in fact chosen since TDLU are
considered to be the units from which precursors of
carcinoma arise.
5.3 Expression of p21 ras in ductal hyperplasias and
carcinomas
5.3.1 Differences between groups
Scores for p21 ras expression in normal epithelium (156
cases), terminal duct hyperplasia without atypia (72),
atypical ductal hyperplasia (33), ductal carcinoma in
situ (63) and invasive carcinomas of all types (86) are
shown in figure 5.9. The number of cases in each group
is given by the bracketed figures above. A trend towards
higher scores is seen with increasing deviation from
normality, and the large majority of carcinomas show
strongly positive staining. This trend is more obvious
in figure 5.10, in which cumulative frequency curves are
plotted. Five curves yield ten comparisons between pairs
of curves and if these are tested for statistical




Figure 5.8. Cumulative frequency curves of scores for
Y13-259 ABC immunostaining. Same data as figure 5.6.
Curves for epithelial cells lie within narrow shaded area
irrespective of position in the duct tree. Myoepithelial
cell curves all lie in the unshaded narrow zone to the


















Figure 5.9. Frequency histograms of scores for Y13-259
ABC immunostaining. a, Normal epithelium of TDLU. b,
ductal hyperplasia without atypia. c, atypical ductal





Figure 5.10. Cumulative frequency curves of scores for
Y13-259 ABC immunostaining. a, normal epithelium of TDLU.
b, ductal hyperplasia without atypia. c, atypical ductal







d p<0.001 p<0.001 p<0.05
d
e p<0.001 p<0.001 p<0.05 p>0.05
Table 5.3. Statistical significance of difference
between curves a-e in figure 5.15, assessed by
Kolmogorov-Smirnov test. The groups referred to are a=
normal epithelium. b= hyperplastic epithelium without
atypia. c= atypical ductal hyperplasia. d= ductal
carcinoma in situ. e= invasive carcinoma.
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Differences between these curves are statistically
significant with the exception of d and e, representing
non-invasive and invasive carcinoma, these curves being
practically coincident; and b and c, representing
hyperplasia without and with atypia. While these curves
are not coincident, the numbers of cases are smaller (72
and 33 respectively) and if epithelial hyperplasias of
usual type (72 cases) are compared with combined atypical
hyperplasias of ductal and lobular types (43 cases),
stronger immunostaining of atypical hyperplasias is
demonstrated (p<0.05). Greater expression of p21 ras
with greater deviation from normality is firmly
established.
Rather than combining scores for extent and intensity of
immunostaining as has been done so far, it is possible to
present the data separately for the same epithelial
populations for which data has been presented in figures
5.8-5.10. This is done in table 5.4 and figure 5.11. In
table 5.4 the raw data is presented while figure 5.11
graphs the percentage of cases on the z axis for each
combination of intensity and extent of immunostaining on
the x and y axes respectively.
A thing of note is that carcinoma cells dying by
apoptosis or coagulative necrosis often show reduced
expression of p21 ras. These phenomena are illustrated
in figures 5.12 and 5.13.
To see whether there is a difference in p21 ras
expression between normal lobules from women with cancer,
and normal lobules from women without cancer, cumulative
scores for epithelial and myoepithelial cells have been
plotted in figure 5.14 for 83 and 72 women in these two
groups respectively. There is no difference.
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Table 5.4. Distribution of cases by individual scores
for intensity and strength of Y13-259 immunostaining. a,
normal epithelium of TDLU. b, ductal hyperplasia without
atypia. c, atypical ductal hyperplasia, d, ductal






























Figure 5.11. Graphical representation of the data
presented in table 5.4. Intensity and extent of
immunostaining are indicated on the x and y axes while
the percentage of cases associated with each score





Figures 5.12. Invasive breast carcinoma. Viable
carcinoma cells express p21 ras strongly. In the area of
necrosis on the left, immunostaining is lost. Scattered
apoptotic cells (arrows) are similarly negative. Y13-
259, 50 ^ig/ml, ABC detection. x250
Figure 5.13. Invasive breast carcinoma. Again, viable
carcinoma cells express p21 ras strongly. Apoptotic






Figure 5.14. Cumulative frequency curves of scores for
Y13-259 ABC immunostaining. a, epithelium of normal TDLU
from 83 women with cancer, b, epithelium of normal TDLU




5.3.2 Vascular and lymph node invasion.
Carcinoma cells in peritumoural lymphatics or venules are
a bad prognostic sign [25], and for this reason p21 ras
expression has been related to the presence or absence of
this feature. There are two ways to do this. Expression
of p21 ras by carcinoma cells within vessels can be
compared with expression by cells of the same carcinoma
outside vessels, in other words those in intimate contact
with stromal cells. Alternatively expression by
carcinomas without vascular invasion may be compared with
expression by carcinomes with it. This section presents
both comparisons. Lymph node status at primary surgery
has also been considered.
An initial attempt to assess blood and lymph vascular
invasion separately was rejected as impractical. It is
not often possible to be certain whether small vessels
are lymphatics or venules. Great care to find
endothelial cells was taken to avoid confusing vessels
with other tissue spaces and only definite examples of
vascular invasion were scored.There were twenty cases in
which PLPD-fixed blocks showed carcinoma in vessels as
well as embedded in stroma. The cumulative scores for
these cases are shown in figure 5.15. The p21 ras score
for carcinoma cells in vessels is less than that of the
cancers which have given rise to them (p<0.05). If these
cases, plus a further nine cases which showed vascular
invasion in diagnostic blocks fixed in Carson's fluid but
not in the PLPD-fixed blocks, are compared with fifty-six
cases which showed no vascular invasion in either PLPD-
fixed or diagnostic blocks, the curves of figure 5.16 are
obtained. There is no difference between these two
curves, and no difference, therefore, in p21 ras
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Figure 5.15. Cumulative frequency curves of scores for
Y13-259 ABC immunostaining. Data for 20 carcinomas with
malignant cells in vessels in blocks scored, a, data for
carcinoma cells in vessels, b, data for carcinoma cells
surrounded by stroma (same 20 cases).
Figure 5.16. Cumulative frequency curves of scores for
Y13-259 ABC immunostaining. a, 29 carcinomas with
vascular invasion, b, 56 carcinomas without vascular
invasion in any block.
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expression by carcinomas with or without vascular
invasion.
Figure 5.17 shows comparable curves for 66 carcinomas
with accurate information about lymph node involvement at
the time of primary surgery. 39 were node-negative, 27
had one or more involved nodes. There is no difference
between these groups. In figure 5.18 the curve for node-
positive cases is split between cases with one or two
positive nodes only (14), and cases with three or more
positive nodes (13). Again there is no difference between
the curves.
5.3.3 Size of primary carcinoma
Size of primary breast carcinoma is also related to
prognosis [58], and its relationship to p21 ras
expression was examined. Accurate sizes (greatest
diameter of the carcinoma in millimetres) were available
for 57 cases, and are shown graphically against p21 ras
score in figure 5.19. There is no correlation. Small
cancers are as likely to express p21 ras strongly as
large ones. Cumulative curves show no difference between
carcinomas smaller or larger than 24mm (this size chosen
as dividing the 57 carcinomas into approximately equal
groups of 29 and 28 cases).
5.3.4 Oestrogen receptor status
Oestrogen receptor status is another variable related to
prognosis [138], and it has been suggested that a
relationship exists between expression of p21 ras and of
oestrogen receptor protein [21]. The oestrogen receptor
data have been provided by courtesy of Dr RA Hawkins of
the Department of Clinical Surgery, Universiy of
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Figure 5.17 Figure 5.18
Figure 5.17. Cumulative frequency curves of scores for
Y13-259 ABC immunostaining. a, Node-negative carcinomas,
b, Node-positive carcinomas.
Figure 5.18. Cumulative frequency curves of scores for
Y13-259 ABC immuno- staining, a, Node negative
carcinomas, b, carcinomas with one or two positive









































Figure 5.19. Greatest diameter of primary carcinoma
plotted against scores for Y13-259 ABC immunostaining.
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Edinburgh. The assay uses a standard dextran-coated
charcoal method [60]. Data for 85 cases are presented in
figure 5.20. Taking 20 fmol/mg as the cut-off between
negative and positive oestrogen-receptor expression, and
separating low p21 ras scores (3,4) from high scores
(5,6,7), there is a relative deficit of oestrogen
receptor negative carcinomas with low p21 ras scores. The
corresponding 2x2 contingency table (table 5.5) gives
chi2 = 5.93, p<0.025.
5.4 Expression of p21 ras in lobular hyperplasias and
carcinomas
Fewer cases are available for study in these groups. If
the scores are plotted as before, a trend towards
stronger expression of p21 ras is again seen with greater
devation of morphology from normality, and this is well
seen in the cumulative score plot, figure 5.21. But
these differences do not attain statistical significance.
5.5 Expression of p21 ras in carcinomas of special type
The distribution of p21 ras scores between carcinomas of
different special types which occurred in the series is
documented in table 5.6. There was no difference between
carcinomas of no special type and those which did belong
to special categories.
5.6 Expression of p21 ras in myoepithelium
As shown in figures 5.6, 5.7 and 5.8, p21 ras
immunostaining is associated with significantly higher
scores in the outer, myoepithelial layer of normal two-
layered breast epithelium at all levels from large ducts
to TDLU. These cells do not often show the fully
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Figure 5.20. Oestrogen receptor protein (fmol per mg of
protein) plotted against Y13-259 ABC immuno-staining. OR




p21 score p21 score
less than 5 5 or greater
[OR]>20fmol/mg 14 39
[OR]< 2 0 fmol/mg 1 31
Table 5.5. Contingency table relating expression of p21
ras and oestrogen receptor in carcinomas. 9C2 = 5.93,
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Figure 5.21. Cumulative frequency curves of scores for
Y13-259 ABC immuno- staining, a, normal epithelium of
TDLU. b, altered lobules without atypia. c, atypical




Type p21 ras score
01234567
Ductal (NST) 1 - - 4 6 12 30 13
Lobular ---21232
Medullary ------2-
Mucoid- _ __i_i_ _
Cribriform -----12-
Tubular




differentiated, elongated form of differentiated
myoepithelial cells but for convenience will be referred
to as myoepithelium nonetheless. Figure 5.22 illustrates
an example of strongly positive staining of elongated
myoepithelium.
5.7 Expression of p21 ras in stromal elements
5.7.1 Stroma of benign tissues
In normal breast, fibroblasts in TDLU and in extralobular
stroma express little p21 ras. Most striking is strong
positivity in smooth muscle of small blood vessels,
illustrated in figure 5.23. Endothelial cells may show
faint positivity, and neural elements also show some
positivity, but not as strongly as vascular smooth
muscle.
Positivity of stromal cells is sometimes more conspicuous
in sclerosing parenchyma, such as sclerosing adenosis and
radial scars. In one case, the cells of an active
granulation tissue formed at the site of a previous
biopsy procedure were strongly positive.
5.7.2 Stroma of carcinomas
In general, most stromal cells of carcinomas showed
positive p21 ras staining which was not so intense as the
staining of carcinoma cells themselves. This
relationship is illustrated in figure 5.24. The
difference between carcinoma cells and supporting stromal
cells is significant (p<0.001) As with epithelial cells,
staining was as much cytoplasmic as membrane-associated.
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Figure 5.22. PLPD-fixed breast tissue, Y13-259 50 jag/ml,
ABC detection. Strong immunoreactivity in myoepithelial
cells. x400
Figure 5.23. PLPD-fixed breast tissue, Y13-259 50 jag/ml,




5.8 Expression of p21 ras in cyst epithelium
A striking difference existed in the expression of p21
ras between different types of cyst. In general,
apocrine cyst epithelium expressed p21 ras strongly. In
some cases this expression was clearly related to the
basal aspect of cells, while in other cases it was
present in the apical portion of the cell (figures 5.25
and 5.26). In contrast, cysts with a flattened
epithelium were devoid of p21 ras expression. Apocrine
and flattened epithelium cysts were present in 29 and 78
cases respectively (figure 5.27).
5.9 Expression of p21 ras in normal parenchyma with age
Proliferative activity in normal breast parenchyma
decreases with increasing age [120]. The relationship of
p21 ras expression to age was examined,and it emerged
that p21 ras expression was a function of age, being more
strongly expressed in younger women. Taking age 45 as a
cut-off, figure 5.28 shows cumulative expression curves
for younger and older women, which differ markedly;
(p<0.01). There is, however, considerable scatter, and
much overlap at all ages.
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Figure 5.24. Cumulative frequency curves of scores for
Y13-259 ABC immunostaining. a, stromal cells of
carcinomas, b, carcinoma cells. p<0.001.
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Figure 5.25. PLPD-fixed breast tissue, Y13-259 50 pg/ml,
ABC detection. Basal immunoreactivity in apocrine cells.
x400
Figure 5.26. PLPD-fixed breast tissue, Y13-259 50 jig/ml,




Figure 5.27. PLPD-fixed breast tissue, Y13-259 50 pg/ml,
ABC detection. There is no immunoreactivity in flattened
epithelial cells. xlOO
Score
Figure 5.28. Cumulative frequency curves of scores for
Y13-259 ABC immuno- staining. Data for unselected




CHAPTER 6 IMMUNOCYTOCHEMISTRY FOR ELECTRON MICROSCOPY:
METHODS
The location of p21 ras within cells was of interest
principally because of the contrast between cytoplasmic
immunostaining of human breast tissue including
carcinomas, and membrane immunostaining in FH05T1 cells.
Membrane localisation in cultured cells expressing p21
ras is well established [147,154], and most discussions
of p21 ras physiology take its membrane location for
granted. But all morphological and biochemical studies
which consider p21 ras location within cells are
concerned with cultured cell lines, often lines
engineered artificially to express large amounts of p21
ras. and there are no published ultrastructural studies
dealing specifically with cells of human tissues, whether
normal or neoplastic. Intracellular location of p21 ras
might be more important than its total quantity, hence
the present studies.
6.1 Pre-embedding ABC staining
A detailed protocol for pre-embedding ABC
immunohistochemistry for electron microscopy is given in
9.7. In brief fixed tissue was cryoprotected by
infiltration with sucrose and glycerol in buffer, and
frozen sections cut at 50pm thickness. This freeze/thaw
cycle makes cells permeable to proteins, and detergent is
not considered necessary for reagent penetration. The
thick sections were processed free-floating in culture
plate wells, using overnight incubations with primary and
secondary antibody and avidin-biotin complex and
prolonged washes before DAB development. The oxidized
DAB polymeric pigment is not of itself electron-dense but
becomes so after osmication. Sections were then embedded
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in Araldite on edge, and thick (lum) sections viewed to
select areas for ultramicrotomy. The results of this
technique were disappointing. Free-floating sections
exposed to primary antibody appeared strongly stained
after development with DAB, while negative controls were
unstained. This signal was faint but visible to a depth
of 5-6|im in toluidine-blue stained thick sections of
Araldite blocks, but when thin sections were viewed by
electron microscopy, it was impossible to distinguish
between test sections and negative controls. Further
osmication of thin sections did not remedy this lack of
signal and this procedure was not pursued. In a
modification of the procedure frozen sections of
similarly fixed and cryopotected tissues were mounted on
gelatin or poly-L-lysine coated slides and immunostained
with a standard ABC method (9.3) and processed for
electron microscopy by an Araldite-capsule technique
[105].
6.2 Pre-embedding immunogold and immunogold-silver
labelling
A detailed protocol for pre-embedding immunogold
immunohistochemistry for electron microscopy is given in
9.9. This method was applied to control cells growing on
cover slips and to cryoprotected frozen sections of
carcinomas on poly-L-lysine coated slides. A two-stage
indirect immunochemical method was used, the second
antibody (goat anti-rat) being adsorbed onto 5nm
colloidal gold particles (Janssen). In the case of
control cells growing on cover slips, a brief exposure to
Triton X-100 in buffer preceded fixation in order to
permeablize the cells. In the case of frozen sections of
cryoprotected tissues this step was omitted. Both
control cells and tissues were processed for electron
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microscopy by the Araldite-capsule method. Parallel test
preparations and negative controls were prepared for
light microscopy with several cycles of silver
enhancement using Janssen's 'IntenSE' kit.
PLPD-fixed paraffin-embedded sections of control tissues
immunostained by a three-stage avidin-biotin-gold complex
method followed by several cycles of silver enhancement
developed a very strong light microscopic signal (figure
4.9). If such sections were reprocessed for electron
microscopy by the Araldite capsule method, conspicuous
labelling was obtained, large silver grains being obvious
at low powers. These particles were about lOOnm in
diameter. Not surprisingly, morphological preservation
was poor.
6.3 Post-embedding immunogold labelling
The detailed protocol for post-embedding immunogold
labelling is given in 9.10. This was an indirect
immunogold method using the same goat anti-rat antibody
adsorbed onto 5nm gold particles. Thin sections were
carried on gold grids. Two embedding media were used:
Araldite and the hydrophilic Lowikryl K4M resin.
Araldite sections were etched with sodium ethoxide to
expose antigenic sites. This was omitted for Lowikryl-
embedded cells. These methods were used on tumours and
on control FH05T1 and CHL cells but without success. No
signal was obtained even with FH05T1 cells. That
immunostaining ought to be possible with Lowikryl K4M was
demonstrated by positive light-microscopic ABC




CHAPTER 7 IMMUNOCYTOCHEMISTRY FOR ELECTRON MICROSCOPY:
RESULTS
7.1 Control tissue
The strongest signal was obtained by gold-silver
immunostaining of paraffin sections of PLPD-fixed FH05T1
tumour reprocessed for electron microscopy. The signal
was predominantly located on the plasma membrane (figure
7.1) but was also present on membranes lining vesicular
spaces in the cytoplasm (figure 7.2). Poor
ultrastructural morphology made it impossible to identify
these structures with confidence. FH05T1 cells growing
on cover slips and exposed to a two-stage indirect
immunogold procedure demonstrated satisfactory
penetration by the 5nm gold probe as judged by electron
microscopy (figure 7.3) and by light microscopy of
identically-treated cover slips which were prepared for
light microscopy by several cycles of silver enhancement.
Results of this process are illustrated in figures 7.4
and 7.5 for FH05T1 cells. The purpose of this experiment
was to examine the distribution of the p21 ras signal in
FH05T1 cells and their parent CHL cells, and incidentally
to look at three other cell lines: A transformed rat
fibroblast line, 208F, which does not express abundant
p21 ras, and two cell lines derived therefrom, known as
RFH05T1 and RFH06N1. Both incorporate Homer vector with
sequences to ensure expression of mutated and normal p21
ras respectively. They are fully described in [122].
This experiment was successful in that preparations for
light microscopy showed good penetration of the probe
into the cells, which is always a cause for concern with
colloidal gold probes even as small as 5nm, and, equally
important, little background signal in negative controls.
But the preparations for electron microscopy were
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Figure 7.1. PLPD fixed paraffin-embedded FH05T1 tumour.
Y13-259 50pg/ml, IGS detection, reprocessed for electron
microscopy. Large silver grains (c. lOOnm) are
predominantly associated with the plasma membrane.
xlO,000.
_ *
Figure 7.2. PLPD fixed paraffin embedded FH05T1 tumour.
Y13-259 50jjg/ml, IGS detection, reprocessed for electron




Figure 7.3. Indirect immunogold labelling of FH05T1
cells growing on cover slips. The signal is more subtle
than in figures 7.1 and 7.2. The signal is membrane-
associated and cytoplasmic. x35,000.
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Figure 7.4. Indirect immunogold labelling of FH05T1
cells growing on cover slips, followed by silver
enhancement. Y13-259 50pg/ml, IGS. x400
#




unsuccessful, except for the FH05T1 and CHL cells,
because the technically exacting Araldite capsule method
failed to harvest cells for ultrastructural inspection.
It was felt that the potential of this method had been
demonstrated.
The p21 ras-expressing cell lines mentioned above showed
both membrane and cytoplasmic staining. This is
difficult to photograph as the flattened shape of cells
adherent to cover slips tends to make membrane-staining
less obvious as it is viewed en face. rather than edge-on
which emphasizesmembrane-staining, as seen in figures 5.1
and 5.2. It was to resolve this difficulty that electron
microscopy was attempted.
7.2 Breast tissue
The results of pre-embedding ABC immunostaining of free-
floating frozen sections and indirect post-embedding
immunogold labelling of thin sections were disappointing,
in that no definite signal was obtained. An attempt to
obtain ultrastructural information on the distribution of
p21 ras in breast carcinoma was made on trucut samples
from carcinomas taken immediately after excision, in the
operating theatre. This avoided any delay before tissue
reached fixative, and the trucut tissue cores were thin
enough for fixative to penetrate rapidly. After fixation
and cryoprotection with glycerol and sucrose in buffer,
cryostat sections were picked up on poly-L-lysine coated
slides and immunostained by ABC and indirect immunogold
methods, osmicated and reprocessed for electron
microscopy by the Araldite-capsule method. Some
immunogold-labelled sections were silver enhanced for
light microscopy. Although some labelling was detected
in sections of osmicated ABC-labelled tissue (figures
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7.6, 7.7), localization was indistinct and did not
resolve the location of p21 ras in breast carcinomas.
This particular group of immunogold preparations for
electron microscopy gave no signal.
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Figure 7.6. PLPD-fixed breast carcinoma. Cryoprotected
frozen section, Y13-259 50 jig/ml, ABC detection,
osmicated, reprocessed for electron microscopy.
Indistinct membrane and possible cytoplasmic staining are
present. xl8,000.





8.1 Ras expression and epithelial breast pathology-
Three immunocytochemical studies [15,41,45] found little
difference in p21 ras expression between benign and
malignant breast tissue, and one study of ras mRNA came
to the same conclusion [152], but evidence opposing this
view is strong [21,27,64,95,119]. The present studies
show consistently greater expression of p21 ras in
carcinomas than normal breast epithelium and relate p21
ras expression to morphological abnormalities associated
with increased risk of carcinoma, that is hyperplasias
especially of atypical ductal and lobular type. This has
only been systematically attempted by one study, on a
smaller scale, by Ohuchi et al [95], whose
immunohistochemical study based on 53 cancer and 46
benign control cases is the largest study of p21 ras
immunohistochemistry in breast excluding the studies
described in this thesis, which are based on 99 cancer
and 72 control cases. They found a gradient of increased
expression from normal epithelium through hyperplastic
and atypical epithelium to carcinoma in situ. On the
basis of their results, Ohuchi et al [95] suggested that
ras gene activation by increased expression might be an
early feature of carcinogenesis. Our results are in
keeping with this view. Ohuchi et ad also noted greater
p21 ras expression in TDLU than extralobular ducts, a
finding which the present studies did not confirm; p21
ras expression was not a function of location within the
ductal tree.
Although there was a relationship between greater p21 ras
expression and epithelial lesions associated with greater
risk of carcinoma, there were striking differences in
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expression between other tissue elements, not easily
related to carcinoma risk, notably expression of p21 ras
in myoepithelial cells and in vascular smooth muscle.
Strong expression in apocrine epithelium was constant
while expression was absent from flattened cyst
epithelium. There are biochemical differences between
the fluids in these two types of cyst [32], and the
present histochemical studies further justify the
separation of apocrine and flattened cysts into
populations with distinct biological properties. The
possibility that one type evolves into the other is not
excluded.
It has been suggested [21,41,81] that increased p21 ras
expression in breast carcinomas is associated with more
aggressive behaviour. Clair et ad [21] found that
patients with tumours shown to express more p21 ras were
less likely to remain disease-free at 4 years than
patients with tumours expressing smaller quantities of
p21 ras. They also found positive correlations of p21
ras with node status and carcinoma size and between
positive oestrogen receptor status and higher p21 ras
levels, but their numbers were small. Fromowitz et al
[41,81] have suggested on the basis of histochemical
studies with RAP-5 that p21 ras expression is related to
histological correlates of aggressiveness (invasion,
vascular invasion) and to the number of positive nodes.
These issues were examined in the present studies and the
results differ from the findings of the workers cited.
Specifically, no relationship was found with carcinoma
maximum diameter; presence or absence of lymph nodes
involved by carcinoma; presence or absence of vascular
invasion; and the relationship with oestrogen receptor
status found in the present studies is the inverse of
that described by Clair et al [21] and DeBortoli et aJL
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[27]. The identical range of p21 ras expression in the
minority of special-type carcinomas and the majority of
no special type is further evidence against a correlation
between p21 ras expression and prognosis in breast
carcinoma.
Our immunohistochemical finding, that p21 ras
immunostaining in intraduct carcinoma and invasive
carcinoma are broadly comparable, is in support of the
finding of Ohuchi et al [95] who used antibody Y13-259,
but contradicts the finding of Fromowitz et aJL, who used
RAP-5 and claimed that p21 ras expression was
consistently greater in invasive than intraduct
carcinoma. In the same paper, it was stated that
expression of p21 ras in carcinoma cells within vascular
spaces was greater than contiguous carcinoma outside
vessels, ie cells with a supporting stroma. The present
studies documented the opposite.
The differences described here from the published
findings of others may reflect several factors. Many
groups have used the antibody RAP-5 in their studies
because the epitope it recognises survives well in
formaldehyde-fixed, paraffin-embedded tissues. Published
studies cast doubt on the specificity of this antibody
for the p21 ras protein [45,103]. It was impossible with
RAP-5 to distinguish on immunoblots between lysates of
FH05T1 and CHL cells, which express p21 ras in high and
low quantities respectively, wheras Y13-259 made this
distinction easily. RAP-5 also failed to differentiate
between acetone-fixed cytospin preparations of FH05T1 and
CHL cells, a test which Y13-259 passed [103], The
conclusion that RAP-5 immunoreactivity has little to do
with p21 ras expression is hard to escape. Other
differences may reflect small numbers of cases in some
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studies, and differences in technique. Walker and
Wilkinson [146] used Y13-259 on acetone-fixed cryostat
sections of breast tissue, with an alkaline
phosphatase/anti-alkaline phosphatase technique. They
found decreased expression of p21 ras in half of the
carcinomas they examined, by comparison with normal
breast tissue. It is difficult to reconcile this to our
findinqs.
8.2 Significance of ras expression in breast
This must remain speculative until the physiological and
biochemical roles of ras are clarified. Expression of
p21 ras in hyperplastic lesions exceeds that in the
surrounding normal TDLU. This suggests a link between
p21 ras expression and proliferation, but this is not
certain in that more cells in a population may follow
decreased cell loss rather than increased production. It
was notable in some carcinomas that cells undergoing
apoptosis showed no p21 ras expression, and in areas of
confluent necrosis, such as in comedonecrotic ductal
carcinoma in situ. cells in the transitional zone between
viable carcinoma and necrotic debris often showed no p21
ras immunoreactivity. Thus a relationship may exist
between lack of p21 ras expression and cell death.
The increased p21 ras expression in carcinomas over
normal breast tissue makes a role for p21 ras in the
evolution of neoplasia possible but whether p21 ras is
directly concerned with the transformed phenotype of
breast cancer cells remains undetermined. One carcinoma
patient showed p21 ras expression in normal parenchymal
epithelium but cells of the carcinoma in the same block
were negative for immunoreactive p21 ras. This example
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proves that quantitative overexpression of p21 ras is not
essential for malignancy in the breast.
Identical curves representing p21 ras scores of intraduct
and invasive carcinoma do not imply identical
quantitative expression. Immunocytochemistry is not
quantitative and intensity of pigment developed by
immunoperoxidase methods is not a linear function of
antigen concentration. Intensity rises steeply with
small increases at low antigen concentrations, but hardly
at all with large increases at higher concentrations
[52]. Expression in DCIS strong enough to give a near-
maximal signal could mask major differences between DCIS
and invasive carcinoma. On the other hand, runs using
greater dilutions of Y13-259 than 50pg/ml suggested that
the immunostaining in DCIS and invasive carcinoma
diminished pari passu and may therefore have been
quantitatively comparable. This would require more
formal studies to resolve.
Although increased expression of non-mutated p21 ras
alone does not transform normal cells, overexpression in
abnormal cells such as NIH3T3 does transform them [100].
Increased expression of p21 ras in breast parenchyma
associated with increased carcinoma risk, ie atypical
hyperplasias and in situ carcinomas, could permit an
abnormality affecting another oncogene, or loss of an
anti-oncogene, to cause neoplastic transformation which
might not develop in the absence of p21 ras
overexpression.
If greater p21 ras expression in breast epithelium
predisposes to breast cancer, then p21 ras expression in
morphologically normal TDLU of cancer patients might be
greater than in TDLU of women without cancer. But breast
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cancer evolves over years to decades, and the parenchyma
which originally gave rise to a carcinoma may have
changed by the time that carcinoma is detected. Data
from the present study show no difference in p21 ras
expression in normal TDLU between women with cancer and
women with benign breast disease, but there is
significantly higher expression in younger women.
Whether p21 ras expression in normal TDLU bears any
relationship to cancer risk remains unclear.
To regard oncogenes as concerned exclusively with
cellular proliferation is to oversimplify their complex
physiology. Injection of p21 ras stimulates DNA
synthesis and cell division in quiescent fibroblastic
cells [35], and antibodies to p21 block this effect. But
injection of p21 N-ras induces neuronal differentiation
in the phaeochromocytoma cell line PC 12 [55] and nerve-
growth-factor induced neuronal differentiation is blocked
by microinjected anti-p21 antibodies.
That p21 ras may influence cell proliferation in the
breast is suggested by the age-related decrease in p21
ras expression in normal TDLU, which parallels the age-
related decrease in thymidine labelling index previously
demonstrated [47]. But this is circumstantial, and
direct evidence dissociates p21 ras expression and
proliferation in some differentiated cellular populations
in the breast. Unfortunately, good thymidine uptake data
are lacking for hyperplastic and atypical lesions in the
breast. Autoradiography shows that myoepithelial cells
of breast do not divide [69], yet myoepithelial cells
with or without the characteristic elongated habit
enfolding parenchymal structures show strong p21 ras
expression. A link with myoid differentiation continues
with p21 ras positivity in vascular smooth muscle and in
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the stroma of sclerosing lesions which show
ultrastructural evidence of myofibroblastic
differentiation [8]. Granulation tissue is a
proliferative tissue but myofibroblastic differentiation
is present ultrastructurally [109] and p21 ras expression
can be conspicuous.
Another notable finding is that p21 ras expression in
carcinoma cells within lymphatic vascular channels is
less than in the parent carcinoma cells which are in
intimate contact with stromal cells. The stromal cells
of invasive carcinomas may show immunoreactivity for p21
ras. and this may reflect interaction with malignant
cells in that stromal cells outwith the carcinomas
usually show little positivity. It seems possible that
expression of p21 ras in carcinoma cells is modulated by
the local environment and in the absence of paracrine
growth factors, such as fibroblast growth factor, its
expression could be downregulated.
8.3 Comparison with ras expression in other systems
It is interesting to compare our breast findings with
other systems in which ras expression has been studied in
well established morphological progressions from normal
through benign changes to malignancy. The adenoma-
carcinoma sequence in large bowel represents
spontaneously occurring human disease while the
papilloma-carcinoma sequence in carcinogen-exposed mouse
skin is an archetype of experimental carcinogenesis.
Several groups have studied ras expression in adenomas
and carcinomas of colon and rectum. In keeping with
increased expression early in the evolution of carcinoma,
Spandidos and Kerr [121] showed increased Ha-ras and Ki-
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ras mRNA in colo-rectal adenomas as well as carcinomas.
The increase in adenomas was sometimes greater than in
carcinomas in the same patients. Gallick et al (1985)
[44] examined p21 ras in Y13-259 immunoblots and showed
greatest levels in early carcinomas. Thor et al [137]
considered that p21 ras expression was greatest in
advanced carcinomas but used antibody RAP-5, so their
conclusions cannot be accepted for reasons discussed in
8.1. Williams et al [153] used Y13-259 for
immunocytochemical studies which showed greatest p21 ras
expression in adenomas while carcinomas showed little
increase in expression compared with normal mucosa. In
their immunocytochemical studies Kerr et al [71] used
Y13-259 and another Furth antibody, YA6-172. They showed
increased expression in adenomas and carcinomas, but less
differential expression between normal and neoplastic
tissues.
Forrester et a]L [40] examined 66 colonic neoplasms by
mismatch cleavage analysis and found K-ras codon 12
mutations in 26 (39 per cent), while NIH3T3 transfection
assay was positive in only 20 per cent. Levels of p21
Ki-ras expression in neoplasms were not related to the
presence or absence of codon-12 mutations. Mutations were
not detected in normal colonic mucosa. This study did
not compare mutation rates between adenomas and
carcinomas. Bos gt al [11] used hybridization analyses
to show ras mutations in 11 of 27 colo-rectal carcinomas,
ten affecting codon 12 of Ki-ras, one codon 12 of N-ras.
In five tumours containing residual adenoma tissue, the
same mutation was present in both adenoma and carcinoma.
A subseguent study [144] showed ras mutations in 9 per




The case for ras mutation playing an important part in
colorectal carcinogenesis is strong. Accurate incidence
data for ras mutation in adenomas which have not made the
transition to carcinoma will clarify the importance of
ras mutations in the adenoma-carcinoma transition.
Quantitative overexpression of p21 ras may still be
important. Balmain and his colleagues have studied the
tumours initiated by treating mouse skin with
dimethylbenzanthracene and promoted with
12-0-tetradecanoyl-phorbol-13-acetate. They have shown a
guantitative increase in Ha-ras message in papillomas and
carcinomas induced in this system, and carcinogen-
specific Ha-ras mutations in both [4,101].
Comprehensive ras mutation data for breast carcinomas are
not available. Spandidos (1987) showed Ha-ras-1
mutations in two of 24 carcinomas using oligonucleotide
hybridization analysis [70]. This relatively low
incidence does not exclude more frequent mutation at
other ras loci and more data are needed before ras
mutation can be dismissed as unimportant in the breast.
There are no published data for pre-malignant breast
lesions. The two systems discussed above illustrate how
important such data may be for understanding of the role
of ras mutation in mammary carcinogenesis.
Recently a new slant on ras activation was demonstrated
by Cohen and Levinson [23]. They showed that the T24/EJ
Ha-ras oncogene owes its strong oncogenic activity not
only to the well-known codon-12 point mutation
[16,102,129,133] but also to a guanine for adenine
substitution of nucleotide 2,719 in the fourth intron.
This substitution increased gene expression tenfold.
Experimental insertion of a sequence including nucleotide
2,719 into the third intron of human growth hormone gene
had the same strong upregulation effect irrespective of
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the promoter, suggesting a widely applicable but
currently unknown mechanism. Such large quantitative
alterations in ras expression could well be biologically
significant. In case the substitution at nucleotide 2,719
was a polymorphism Cohen and Levinson sought but did not
find it in 44 samples of human genomic DNA. They did,
however, find that other substitutions in the same region
could affect ras expression. Such studies suggest a
possible mechanism altering the expression of different
ras alleles, with relevance to their potential for
oncogenic activation.
8.4 Cellular location of p21 ras
Little attention has been paid in the literature to the
cellular location of p21 ras. It is generally accepted
that p21 ras is a cell-membrane protein, but this cell-
membrane relationship is only seen clearly in cell lines,
often artificially engineered. In many immunocytochemical
studies of p21 ras expression in genuine tissues, the
detected immunoreactivity is predominantly cytoplasmic,
not membrane-related, but this location has attracted
little attention. It may have been assumed that
cytoplasmic staining reflects antigenic diffusion from
the original site in the cell, ie the cell membrane.
But p21 ras is not a labile protein. In cultured cells
it has a long half life, and it is securely attached to
the inner face of the plasma membrane. When Grand et al
[54] wished to detach p21 ras from the cell membrane of
cells engineered to express abundant p21 N-ras. they had
to use powerful membrane-disrupting detergents like
Triton-XlOO to extract it. These are not the properties
of a labile protein liable to diffuse rapidly from its
normal site in the presence of fixing agents. And in the
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case of FH05T1 cells and their derived tumours, we know
that the fixatives PLP and PLPD give a strong membrane
signal with little cytoplasmic staining. It seems that
the distribution of p21 ras in normal human tissues and
in carcinoma cells is different from the distribution in
engineered cell lines, which as model systems may poorly
reflect the physiology of human p21 ras expression. The
recent discovery of the GTPase activating cytoplasmic
protein, GAP [14,139], which may be an upstream regulator
of p21 ras but could be the long-sought downstream target
of p21 ras [114], emphasizes the importance of this
localization guestion. If the target of p21 ras is a
cytoplasmic protein, p21 ras might not need to be
confined to the cytoplasmic membrane to exert
physiological or patho-physiological effects. If the
physiology and pathophysiology of p21 ras are to be
elucidated in tissues, attention must be paid to the
localization of p21 ras in such cellular populations, and
not just in cell lines.
8.5 Future studies
It would be desirable to study other oncogenes and to
relate their expression and that of growth-factor and
growth-factor receptors to precursor lesions of breast
cancer. The c-erbB2 gene and its rodent homologue, c-neu,
are particularly interesting. A point mutation in the
transmembrane domain activates c-neu [7]. Muller et a_l
[91] recently showed that a strain (TG.NF) of transgenic
mice bearing activated c-neu fused with mouse mammary
tumour virus (MMTV) promoter invariably develop
metastasizing mammary gland adenocarcinomas. In these
mice the entire mammary epithelium overexpresses pl85 neu
and undergoes malignant transformation. In a second
strain (TG.NK) pl85 neu expression and neoplastic
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transformation are less frequent, but pl85 neu is
overexpressed in all carcinomas which do develop. These
results contrast with transgenic mice carrying MMTV/ras
and MMTV/myc [127] fusion genes in which mammary
carcinomas are less common and develop stochastically.
Even when ras and myc genes are co-expressed, and act
synergistically [115], further events appear necessary
for malignant transformation, while overexpression of
activated neu alone is sufficient for oncogenesis. The
effects of neu were tissue specific. Epithelial
hyperplasia occurred in parotid gland and epididymis, but
neoplasms did not occur in these sites of neu
overexpression. These findings and the relationships
between erbB2 expression and human breast cancer [73,116]
suggest that c-neu/erbB2 will be an important target for
investigators. The present data suggest that increased
ras expression may be important in breast carcinogenesis.
Is such expression essential, or do other genes, such as
erbB2. mediate similar effects? Questions concerning
breast carcinogenesis which will require answers before a
unified picture can emerge include possible relationships
between ras and erbB2 expression, and whether erbB2 is
capable of one-step malignant transformation in the human
breast.
The present studies confront the problem of quantifying
immunohistochemical staining. The scoring system used is
probably as complex as essentially non-quantitative
peroxidase-based immunochemical methods justify.
Although IGS staining did not offer greater sensitivity
for detection of this particular antigen, it might be the
basis for quantifiable detection. Supra-optimal
dilutions of primary antibody, a second-stage colloidal
gold reagent labelled with protein G or protein A (which
combine with single antibody molecules), followed by
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high-gain enhancement with silver to render each
colloidal gold nucleus visible to light microscopy, might
permit guantifiable grain counting. Rigorous controls
would be necessary but the information yielded might
justify the effort involved.
The distribution of p21 ras in cells has been little
investigated and its exploration would of great interest.
Immunoelectron microscopy is exacting and the present
studies only began to explore this area. Video enhanced
contrast microscopy permits visualization within living
cells of colloidal gold probes as small as 5nm
[28,29,113] and would be a potent tool for investigating
dynamics of p21 ras expression in cultured cells.
The importance of ras mutation to carcinogenesis in the
breast remains an area in which more information is




9 PROTOCOLS FOR EXPERIMENTAL PROCEDURES
9.1 Carson's fixative
This fixative was devised to give adequate fixation for
electron microscopy as well as being suitable for routine
histological use [17]. It is a minimally modified
Millonig's phosphate buffered formaldehyde solution, the
buffer system being dibasic sodium phosphate and sodium
hydroxide. The pH is neutral and osmolality excluding
formaldehyde is 290.
Composition per litre:
Technical grade 37-40% Formaldehyde 100.0ml
Monobasic sodium phosphate 18. 6g
Sodium hydroxide 4.2g
Tap water 900.0ml
Carson found neither 'commercially pure' 37-40 per cent
formaldehyde (which like most 37-40 per cent formaldehyde
solutions contains 10-15 per cent methanol for
preservation), nor formaldehyde prepared from
paraformaldehyde, nor deionized water, gave better
morphology.
9.2 Periodate-lysine-paraformaldehyde (PLP)
and its dichromate derivative (PLPD)
PLP was described by McLean and Nakane [89]. As it does
not keep, it is better to prepare small quantities.
To make up 100ml of PLP.
0.05M phosphate buffer 100.0ml







The 0.05M phosphate buffer has this composition:
Dibasic sodium phosphate, dihydrate





8 per cent 'paraformaldehyde' solution is prepared by
suspending 40g of paraformaldehyde in 500ml of deionized
water at 70C and adding 500mg of sodium hydroxide (five
pellets). The polyoxymethylene paraformaldehyde polymer
is dissociated by this process yielding a methanol-free
formaldehyde solution.
To prepare periodate-lysine-paraformaldehyde-dichromate
(PLPD), PLP is diluted with an equal volume of 5 per cent
potassium dichromate in water. This fixative was
introduced by Holgate et ad [63].
9.3 ABC Immunostaining for light microscopy
Cut four micron sections from paraffin blocks
Dry at 50C overnight
Dewax in xylene 10 minutes
Rehydrate through graded alcohols to tap water
Transfer to TRIS buffered 0.9 per cent saline (TBS)
Dry round sections and transfer to humid chamber
Apply 10 per cent normal goat serum
in TBS (NGS/TBS) 5 minutes
Drain excess NGS/TBS and dry round sections
Apply Y13-259 1:50 in NGS/TBS 60 minutes
Wash in TBS in Steiner vessel on rocker 2x5 minutes
Apply NGS/TBS 5 minutes
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Drain excess NGS/TBS and dry round sections
Transfer to humid chamber
Apply biotinylated goat-anti-rat IgG 1:50
in NGS/TBS
Wash in TBS in Steiner vessel on rocker
Dry round sections and transfer to humid
chamber. Apply avidin-biotin complex
(Amersham) 1:200 in TBS or Dako ABC reagent
Wash in TBS in Steiner vessel on rocker
Develop with diaminobenzidine-hydrogen
peroxide in TRIS-imidazole buffer









Stock solution of TRIS,
(Tris(hydroxymethyl)aminomethane), MW 121.14. Dissolve
30.3g in 500ml of DDW. Add 1 Molar HCl until pH = 7.6.
Approximately 200ml will be needed. Dilute to 2L. Molar
HCl contains 85ml of concentrated acid per litre. To
make up TRIS-buffered saline (TBS), dilute tenfold with
0.9 per cent NaCl in DDW.
9.5 TRIS-imidazole buffer and peroxidase development
0.1 Molar HCl 38.0ml
0.2 Molar TRIS 24.0ml
DDW 38.0ml
Imidazole (MW 68.1) 68.1mg
Final pH should be 7.6. If a detergent such as Triton X-
100 is incorporated at low concentration (0.05 per cent)
in the buffer, it is easier to wet sections evenly which
gives more uniform development. lmg/ml of
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diaminobenzidine (DAB) in TRIS-imidazole buffer is
activated with 5pl/ml of 100 volume hydrogen peroxide
immediately before use.
9.6 Immunogold-silver staining for light micoscopy
9.6.1 Indirect (2-stage) immunogold-silver staining
Cut four micron sections from paraffin blocks
Dry at 50C overnight
Dewax in xylene 10 minutes
Rehydrate through graded alcohols to tap water
Transfer to TRIS buffered 0.9 per cent saline (TBS)
Dry round sections and transfer to humid chamber
Apply 10 per cent normal goat serum in
TBS (NGS/TBS)
Drain excess NGS/TBS and dry round sections
Transfer to humid chamber
Apply Y13-259 1:50 in NGS/TBS
Wash in TBS in Steiner vessel on rocker
Apply NGS/TBS
Drain excess NGS/TBS and dry round sections
Transfer to humid chamber
Apply LM grade goat anti-rat IgG-colloidal-
gold (Janssen) 1:50 in NGS/TBS
Wash in TBS in Steiner vessel on rocker
Wash in deionized distilled water (DDW)
in Steiner dish on rocker
Enhance (control under staining microscope)








Enhance sections with Janssen's 'IntenSE' or 'IntenSE II'
kit as per manufacturer's instructions. The pH of the
'IntenSE' reagent is low (3.2) and a stronger signal
results if sections are post-fixed in 2 per cent
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glutaraldehyde in PBS (not TBS) before enhancement. Wash
in running tap water for ten minutes after post-fixation
then proceed with washes in DDW. IntenSE II reagent has
neutral pH.
9.6.2 Immunogold-silver staining with streptavidin-
biotin-gold complex
Cut four micron sections from paraffin blocks
Dry at 50C overnight
Dewax in xylene 10 minutes
Rehydrate through graded alcohols to tap water
Transfer to TRIS buffered 0.9 per cent saline (TBS)
Dry round sections and transfer to humid chamber
Apply 10 per cent normal goat serum
in TBS (NGS/TBS) 5 minutes
Drain excess NGS/TBS and dry round sections
Transfer to humid chamber
Apply Y13-259 1:50 in NGS/TBS 60 minutes
Wash in TBS in Steiner vessel on rocker 2x5 minutes
Apply NGS/TBS 5 minutes
Drain excess NGS/TBS and dry round sections
Transfer to humid chamber
Apply biotinylated goat-anti-rat IgG 1:50
in NGS/TBS 30 minutes
Wash in TBS in Steiner vessel on rocker 2x5 minutes
Dry round sections and transfer to humid chamber
Apply streptavidin-biotin-gold complex (Janssens)
1:50 in TBS 30 minutes
Wash in TBS in Steiner vessel on rocker 3x5 minutes
Wash in deionized distilled water (DDW)
in Steiner dish on rocker 6x2 minutes
Enhance (control under staining microscope)
Counterstain, Dehydrate, Clear, Mount
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9.7 Pre-embedding ABC immunostaining for electron
microscopy-
Fix thin tissue blocks overnight in PLP or PLPD at 4C
Wash in Sorensens phosphate buffer,
pH 7.4 (SPB) 4x2 hours
Cryoprotect by immersion in the following series:
5 per cent glycerol, 10 per cent sucrose
in SPB 30 minutes
10 per cent glycerol, 15 per cent sucrose
in SPB 60 minutes
10 per cent glycerol, 20 per cent sucrose
in SPB Overnight
Freeze onto cryostat chuck with OCT
Cut thick frozen sections (50-100um)
All subseguent manipulations are on free-floating
sections in culture-plate wells. Reagents are
conveniently added and removed with a cut-down pipette
tip fitted to a 5ml syringe. Needles catch sections and
are better avoided.
Wash in SPB or TBS
Suspend NGS/TBS




Replace with biotinylated goat-anti-rat IgG
1:50 in NGS/TBS; keep at 4C
Wash in TBS
Suspend in ABC as for light microscopy
Wash in TBS














Replace with DAB-TRIS-imidazole buffer
with H202
Wash in TBS
Osmicate in one per cent 0s04




9.8 Sorensen's phosphate buffer pH 7.4
Potassium dihydrogen phosphate, anhydrous 3.6g
Disodium hydrogen phosphate dihydrate 19.Og
DDW 2.0L
9.9 Pre-embedding immunogold labelling for electron
microscopy
This technique was applied to cultured cells grown on
coverslips, not to tissue sections. Make up fixative
containing 2 per cent paraformaldehyde, 0.1 per cent
glutataldehyde, 0.1 per cent Triton X-100 in Sorensen's
phosphate buffer (SPB); also 0.1 per cent Triton X-100 in
SPB, and SPB alone.





Drain and apply Y13-259 1:50 in NGS/TBS
Wash in TBS
Apply NGS/TBS
Drain and apply EM-grade goat-anti-rat IgG
5nm colloidal gold probe 1:5 in NGS/TBS
Wash in TBS
Wash in SPB












in cacodylate buffer 10 minutes
Process for electron microscopy
9.10 Post-embedding immunogold labelling for electron
microscopy
Fix tissue in PLP or PLPD, wash in buffer, embed in
Araldite, or Lowikryl or other hydrophilic resin.
Collect sections of gold interference colour
onto gold grids
Etch with fresh saturated NaOH in ethanol 6-8 seconds
Rinse in two changes of sterile DDW
Check sections have survived sodium ethoxide etching
Apply normal goat serum (NGS) 1:30 in phosphate
buffered saline (PBS) containing 1 per cent bovine
serum albumin and 0.01M glycine (PBSAG) 10 minutes
Transfer to Y13-259 1:50 in PBSAG Overnight
Wash in PBS 6x5 minutes
Apply PBSAG 10 minutes
Transfer to EM-grade goat-anti-rat IgG
5nm colloidal gold probe 1:10 in PBSAG 60 minutes
Wash in PBS 6x5 minutes
Wash in sterile DDW 6x2 minutes
Transfer to saturated uranyl acetate 10 minutes
Rinse in sterile DDW
These manipulations are conveniently performed in drops
on a slab of dental wax. The etching stage is omitted
for material embedded in hydrophilic resins. Solutions
should be filtered through an 0.2um Millipore filter




Gels were poured from 2 per cent low-melting-temperature
agarose in PBS containing 0.1 per cent sodium azide,
mixed with an equal volume of goat anti-rat IgG (Sigma)
diluted in PBS-azide. Undiluted antibody was certified
by Sigma to precipitate 0.92mg of rat IgG per ml and gels
were prepared at final dilutions 1:10, 1:20, 1:40, 1:100.
Best results were given at 1:20. 3ml gels were poured on
plain glass slides 40x75mm on a levelling table. Ten 5ul
wells were cast with a specially made former. Test
samples were placed in the wells and the gels kept at 4C
for 48 hours. Ring diameters were read with a graduated
magnifying eyepiece.
Gels were stained for one hour with the following
solution:
Coomassie Brilliant Blue
or Kenacid Blue R 1.Og
Methanol 225.0ml
Glacial acetic acid 50.0ml
Deionized distilled water to 500.0ml
And destained until appropriately differentiated in:
Methanol 225.0ml
Glacial acetic acid 35.0ml
Deionized distilled water to 500.0ml
Gels could be air-dried without measurable change in ring
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CHAPTER 11 DATA APPENDIX
This chapter lists patient data in three tables. The
first (ll.l) lists patient biopsy accession numbers (UB
numbers), birth date, biopsy date, side and operative
procedure. Dates are given in standard computer format
(year, month and day being presented in that order as a
six digit number) to facilitate data processing. Also
given are numbers (prefixed by A or B) which identify
cases rather than the more cumbersome UB numbers. In
this table the last column lists lesions not specifically
included under their own column heading in table 11.2
(see below).
Table 11.2 uses A or B number as sole patient identifier.
It lists final scores allocated to p21 ras immunostaining
for all elements scored. This table represents therefore
a compendium of structural elements present in each case.
In some cases other diagnoses are mentioned where
relevant in the last column. Each column is headed by a
capital or lower case Roman letter. These are the key to
the element represented in that column, and what they




A No UB No DOBx DOB
A 1 8616435 860812 380713
A 4 8616935 860819 330426
A 5 8617163 860821 410307
A 7 8617443 860826 540209
A 12 8618127 860904 331212
A 15 8619025 860918 470227
A 16 8619805 860930 400716
A 28 8621655 861024 620527
A 31 8621834 861028 380206
A 32 8621833 861028 380108
A 33 8622058 861030 390213
A 34 8622059 861030 310719
A 35 8622408 861104 380603
A 36 8622961 861111 440305
A 37 8623288 861113 410304
A 38 8623289 861113 480602
A 39 8623290 861113 311112
A 40 8623292 861114 560119
A 41 8623473 861117 170819
A 42 8623545 861118 311122
A 43 8623544 861118 400428
A 44 8623819 861120 450202
A 72 8703744 870223 220830
A 73 8703950 870224 510309
A 74 8704823 870305 510914
A 76 8704825 870303 321006
A 77 8705040 870309 380225
A 78 8705079 870310 301219
A 79 8705443 870313 640807
A 80 8705444 870313 640202
A 81 8705693 870316 570526





































A No UB No DOBx DOB
A 83 8706735 870330 350619
A 85 8706981 870402 390419
A 86 8701765 870406 370629
A 87 8707324 870408 481226
A 88 8707855 870414 500705
A 89 8707954 870416 450617
A 90 8707951 870416 311107
A 91 8707953 870416 680122
A 92 8708552 870423 450109
A 93 8708740 870427 440312
A 94 8709026 870430 440809
A 95 8709248 870501 690125
A 96 8709488 870505 450528
A 98 8709030 870505 371124
A 99 8709731 870511 440103
A100 8709730 870511 201024
A102 8609924 870512 321201
A10 3 8710051 870512 450101
A104 8710049 870512 360114
A106 8710188 870515 250501
A112 8710733 870521 431210
A114 8711008 870526 650522
All 6 8711715 870604 230315
A117 8712170 870609 410516
A118 8712406 870612 220526
A119 8712640 870616 231204
A120 8712812 870618 451206
A121 8712813 870618 190912
A122 8713149 870623 440209
A123 8713150 870623 280420
A12 4 8713148 870623 440106





































A No UB No DOBx DOB
A126 8716164 870804 420924
A127 8716165 870804 370530
A128 8716664 870811 300506
A129 8716665 870811 200320
A130 8716666 870811 440815
A131 8716838 870815 530510
A132 8717169 870818 251231
A13 3 8717783 870825 151031
A13 4 8717782 870825 470224
A13 5 8718029 870827 520720
A13 6 8718030 870827 370123
A137 8718320 870901 180707
A13 8 8718321 870901 500219
A13 9 8718322 870901 440810
A140 8718576 870903 570616
A141 8718578 870903 441222
A142 8718579 870902 380802
A143 8718827 870907 461222
A144 8719591 870915 480706
A147 8720097 870924 310612
A148 8720207 870925 620305
A149 8720325 870928 570703
A150 8720462 870929 090219
A151 8720625 871001 441223
A152 8720996 871006 300506
A153 8720924 871006 370418
A154 8720925 871006 440727
A155 8721210 871008 260329
A156 8721552 871012 600604
A157 8721471 871013 240731
A158 8721520 871013 391002





































A No UB No DOBx DOB S
A160 8722059 871020 420111 -
A161 8722149 871020 300305 R
A162 8722151 871020 591115 L
A163 8722473 871023 640202 R
A164 8722620 871026 440206 R
A165 8722622 871027 470101 L
A166 8722726 871027 210620 L
A167 8722658 871027 380306 L
A168 8722659 871027 444082 L
A169 8722727 871027 300308 R
A17 0 8722950 871029 520204 L
A172 8722951 871029 430204 R
A173 8723323 871103 631004 R
A174 8723212 871103 330528 R
A176 8723603 871105 320423 L
A177 8723514 871105 390827 R
A17 8 8723870 871109 530307 L
A179 8723871 871110 301123 L
A180 8724479 871117 430818 R
A181 8724488 871117 201112 R
A182 8724819 871119 460212 L
A18 3 8724902 871120 570914 L
A184 8724903 871120 550102 L
A186 8725068 871124 520101 R
A187 8725046 871124 351124 R
A188 8725069 871124 360423 -
A189 8725125 871124 280924 R
A192 8726387 871208 550615 L
A193 8726249 871208 320203 -
A194 8726255 871208 200605 L
A195 8726554 871210 081006 L




































A No UB No DOBx DOB
A197 8726918 871215 520727
A198 8727153 871218 430526
A199 8727035 871218 130913
A200 8727422 871222 570601
A202 8800233 880106 150423
A203 8800290 880107 440616
A204 8800603 880112 460424
A205 8801070 880109 480325
A206 8801026 880119 331122
A207 8801321 880121 440129
A208 8801486 880126 521222
A209 8801559 880126 '201107
A210 8801560 420216 420216
A211 8801556 880126 421016
A212 8801557 880126 551108
A213 8802211 880204 191228
A214 8802212 880219 400629
A215 8802213 880204 400824
A216 8802591 880211 560127
A217 8802942 880216 590815
A218 8803102 880218 300617
A219 8803103 880218 311122
A220 8804191 880304 680304
A221 8805019 880324 420407
B 1 8612685 860619 300925
B 2 8610486 860522 370225
B 3 8612060 861206 330323
B 4 8613452 860701 381119
B 5 8610277 860520 380419
B 6 8610030 860515 400529
B 7 8615436 860729 570608





































A No UB No DOBx DOB S Op Other
B 9 8612556 860619 320603 L —
B 11 8611010 860529 110318 L —
B 12 8611538 860606 171231 R —
B 13 8610029 860515 390604 L —
B 14 8612107 860612 160320 R —
B 15 8518938 850919 420111 - —
B 16 8613132 860626 531018 L — Fibroadenoma
B 17 8611011 860529 291016 L —
B 18 8525261 860513 550920 L — Lactational
B 19 8605967 860318 470929 R —
B 20 8523790 851125 460824 R —
B 21 8524727 851206 520816 L —
B 22 8702210 860218 240525 R — Fibroadenoma
B 23 8603615 860218 500304 L —
B 24 8601644 000000 000000 L —
B 25 8612106 860612 480628 L —
B 26 8611537 850605 350315 R —
B 27 8716838 850813 530510 R — Papilloma
B 28 8605968 860318 380512 — —
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A B C D E F G H I J K L M N 0 P Q R S T U V W X Y
A126 2 4 3 3 2 0 4 3
A127 4 4 2 2 2 4 5 - - - - - 0 - - - 3 - 4 - - - - - -
A129 2 4 0 0 2 - - - - - - - 0 - - - - 5 - 5 6 5 - - -
A130 4 5 3 3 2 2 5 4
A131 4 5 3 4 1 0 5 4
A13 2 3 5 3 3 1 3 5 - 4 - - - 0 5 - 6 - 7 - 1 6 4 - - -
A13 3 0 0 0 2 1 2 5 4 - - -
A134 0 2 0 0 2 2 0 2
A13 5 2 2 2 2 2 - - - - - - - - - - 3 - 7 - 1 7 6 - - -
A136 2 2 2 2 1 0 3 2 - 3 - - 2 7 5 - - -
A137 1 2 - - - - - - - - - - 0 - - 5 5 - - 1 6 4 - - -
A138 4 5 0 5 4 5 5
A139 3 5 3
A140 3 2 2 2 4
A141 3 4 3 3 2 3 3 4 - - - - 0 4 4 6 - 6 - 1 6 4 - - -
A142 4 5 3 3 2 - - - - - - 5 0 4 - 4 - 5 - 5 5 4 - - -
A143 0 2 0 0 2 - - - - - - - 4 2 - - - 6 - 1 6 4 6 - -
A144 3 5 2 2 - - - - - - - - 0 - 2 2 - 5 - 1 5 4 - - -
A147 3 4 1 1 2 - - - - - - - 0 - - - - 5 6 2 6 5 - - -
A148 5 5 4 3 1 6
A149 5 6 3 3 2 4 0 6
A150 3 2 2 2 2 - - - - - - - 1 2 - - 4 - - - - - - - -
A151
A152 3 3 2 2 2 5 0 2 2 - 3 - 6 2 6 4 - - -
A153 2 4 2 2 2 3 3 3 - - - - 0 3
A154 3 6 3 3 2 - - - 5 6 6 7 0 4 3 4 - 4
A155 3 4 - - 2 - - - - - - - - - - - - 5 - 1 5 4 - - -
A156 4 4 3 6 - - - - - - - - 2 - 2 - - - - - - - - - -
A157 2 3 1 1 2 - - - - - - 0 0 4 - 4 3 - 5 2 5 4 4 - -
A158 4 6 3 3 2 5
A159 3 5 - - - 3 5 - - - - 2 0 4 3




A B C D E F G H I J K L M N 0 P Q R S T U V W X Y
A161 3 5 2 2 2 7 7 2 3 5 5-7 — 1 7 7 5 — —
A162 3 4 - - - 5 5 5 - - - 6 3 4 6
A163 3 6 2 2 2
A164 3 5 3 3 2
A165 0 0
A166 6 7 3 3 1 - - 5 3 5 7
A167 3 4 3 3 1 - - - 7 5-4 0 2 4
A168 5 6 2 2 2 5
A169 3 4 2 2 1 4 5 - - - - - - 5 - - - - - 1 6 7 - - -
A170 4 5 - - 5 - 1 7 7 - - -
A172 3 4 - - 7 - 1 6 4 - - -
A173 3 5 3 2 2 1 4 3 3 - -
A174 2 3 0 0 2 - - - - - - - 0 - 2 4-5 - 1 6 6 3 - -
A176 2 5 2 2 1 - - 7 - 1 6 7 5 - 7
A177 4 6 2 2 1 2 5 4 4
A178 5 5 1 1 2 1 4 4 4 - -
A179 2 6 2 4 1 - - 2 0 3 4 7-7 - 1 5 7 5 - 5
A180 4 4 4 5 1 - - - - - - - 0 - - - - 6 - 1 7 6 7 - -
A181 4 4 3 3 1 6 6 - - -
A182 4 5 3 4 2 0 4
A183 4 5 0 0 1 4 4
A184 4 4 1
A186 3 5 4 4 2 6 2 4 4 - - -
A187 3 6 3 3 2 - - - - - - - 0 - 3 - 5 - - - - - - - -
A188 4 5 2 2 2 - - 5 2 6
A189 2 6 3 3 2 4 4 - - _ _ _ 0 4 - - - 6 - - - - - - -
A192 5 5 2 2 2 - - 7 - 1 7 7 - - -
A193 5 5 4 4 2 - - - 5 5 - - 0 4 - 6-7 - - - - - - -
A194 2 4 1 2 1 - - - - - - - - 4 - 5 - - - 1 5 6 - - -
A195 4 4 0 2 1 - - - - - - - - - - 5-5 - 1 5 5 - - -
A196 4 5 4 3 1 0 5 5
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C Lobular stromal cells
D Extralobular stromal cells
E Vascular smooth muscle
F Sclerosing adenosis: Epithelium
G Sclerosing adenosis: Myoepithelium
H Sclerosing adenosis: Stroma
I Radial scars: Epithelium
J Radial scars: Myoepithelium
K Radial scars: Stroma
L Cyst epithelium: Apocrine
M Cyst epithelium: Flattened
N Hyperplastic epithelium: Ductal without atypia
0 Hyperplastic epithelium: Altered lobules
P Hyperplastic epithelium: Atypical ductal
Q Hyperplastic epithelium: Atypical lobular
R Ductal carcinoma in situ
S Lobular carcinoma in situ
T Invasive carcinoma: Type
U Invasive carcinoma cells
V Stromal cells of carcinoma
W Carcinoma cells within lymphatics
X Carcinome cells in venules
Y Carcinoma cells in lymph nodes
Table 11.3. Column headings for table 11.2.
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SUMMARY
Specific immunostaining of p21 ras protein by the well-characterized pan-rus antibody Y13-259 is achieved in
paraffin sections ofhuman and animal tissues fixed in periodate-lysine-paraformaldehyde-dichromate (PLPD). Inten¬
sity of staining is as good as in cryostat sections, with superior histological detail. Localization to plasma membrane is
demonstrated in rodent cells genetically manipulated to express abundant p21 ras (the FH05T1 cell line), both in
preparations suspended in agar after culture in vitro and in those growing as tumour in vivo. Strong positive staining is
observed in neoplasms of human breast and colon, tissues in which there is independent evidence of elevated ras gene
expression. The superior morphology afforded by this technique allows clear characterization of p21 ras expression in
small premalignant lesions for which other methods of detection of oncogene expression are not appropriate.
key words—p21 ras, immunochemistry, fixation, monoclonal antibody Y13-259.
INTRODUCTION
The well-characterized monoclonal antibody
Y13-2591'2 reacts with an epitope, probably amino
acids 70-81,2 shared by the 21 kDa protein products
ofmutationally activated and non-mutated Harvey
(Ha), Kirsten (Ki), and N-rrw oncogenes. These
proteins, collectively known as p21 ras, are GTP
binding proteins located on the inner face of the
plasma membrane3'4 and are believed to be
involved in transduction of extracellular signals.5
Y13-259 has been used in several studies of ras
oncogene expression, but in our experience and that
of others6'7 the epitope detected survives formal¬
dehyde fixation poorly. Most but not all immuno-
cytochemical studies with Y13-259 have used
cryostat sections fixed in acetone.6'8'9 Attempts to
raise other monoclonal antibodies to ras peptides
suitable for use in conventionally fixed, paraffin-
processed tissues have not proved successful so
Addressee for correspondence: Dr J. J. Going, Department of
Pathology, University Medical School, Teviot Place, Edinburgh
EH8 9AG, U.K.
far,10 although polyclonal antisera with suitable
immunoreactivity exist.7
In view of reports of ras mutation and hyper-
expression in neoplasms of the human colon and
breast, it is particularly important that immuno-
cytochemical methods should exist for detection
of p21 ras products with high specificity and good
tissue localization. To be useful in the study of
oncogene expression in premalignant lesions, such
methods should be applicable to small tissue
samples. Such samples are usually unsuited to bio¬
chemical analysis. In this paper, we report immuno-
cytochemical demonstration of p21 ras using
Y13-259 in paraffin sections of tissue fixed with
periodate-lysine-paraformaldehyde (PLP) and its
dichromate derivate (PLPD). These fixatives are
known to allow demonstration of lymphocyte anti¬
gens in paraffin-embedded tissues, using antibodies
hitherto reactive only in cryostat sections.11 They
appear to be particularly suited to demonstration of
membrane-associated antigens. The validity and
potential usefulness of these fixatives are demon¬
strated in animal cells known to express p21 ras at
high levels, and in human colon and breast tissue.
0022 3417/88/070185 -06 $05.00
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MATERIALS AND METHODS
Fixatives
Stock 8 per cent paraformaldehyde was prepared
by stirring 8 g/100 ml into deionized distilled water
(DDW) at 70°C, adding lOOmg of sodium hydrox¬
ide for each 100 ml of solution, stirring until the
solution cleared, and filtering. This solution is stable
at room temperature. Stock 0 05 m phosphate
buffer, pH 7-7, contains 0 0367 m dibasic sodium
phosphate (Na2H P04) and 0-0133 m monobasic
sodium phosphate (NaH2P04 in DDW. On the day
of use, 200 ml batches of PLP were prepared
by dissolving 2-74 g of anhydrous L-lysine mono-
hydrochloride and 0-43 g of anhydrous sodium
metaperiodate in a mixture of 50 ml of 8 per cent
paraformaldehyde and 150 ml of phosphate buffer.
This gives a solution with the composition described
by McLean and Nakane12 and a pH of 6-2,
although their preparative method differed in
detail. PLPD was prepared by dissolving 2-5 per
cent w/v of potassium dichromate in PLP diluted
with an equal volume of DDW. Other fixatives
have included 2 per cent glutaraldehyde, 4 per
cent neutral buffered formaldehyde, and Carson's
fixative.13
Cell lines and experimental tumours
The CHL and LH05T1 cell lines have been
described previously.14 Briefly, the LH05T1 cell
line was derived by transfection of an early passage
embryonic Chinese hamster lung fibroblast strain
(designated CHL) with the plasmid pH05Tl, which
contains the mutationally activated human T24
Harvey-ras oncogene ligated to viral enhancing se¬
quences. The resulting fully transformed LH05T1
cell line is tumorigenic in immune-deprived mice.
Quantitation ofHa-raymRNA by dot-blot hybridi¬
zation has shown 20-60 fold increased ras transcript
in LH05T1 cells and derived tumours, compared
with parental untransformed CHL cells, and high
levels of the p21 ras protein product have been
confirmed by immunoblotting of LH05T1 cell
extracts.15
LH05T1 and CHL cells were maintained in
Dulbecco's modification of minimum Eagle's
medium, containing 10 per cent newborn calf
serum, penicillin, and streptomycin. Cell suspen¬
sions were prepared from monolayers by treatment
with 0-02 per cent EDTA and 0-1 per cent trypsin
Dulbecco's phosphate-buffered saline (PBS) and
washing in PBS. Approximately 5 x 106 cells were
fixed in PLPD for 15 min at 4°C, washed in PBS, and
resuspended in 0-5 ml of 2 per cent low-melting-
temperature agarose (LML Bioproducts) in PBS at
40°C. After setting, this pellet was post-fixed for up
to 24 h in PLPD, washed in PBS, and processed to
paraffin without raising the temperature higher than
56°C.
Subcutaneous tumours were engendered in
immune-deprived mice by inoculation of LH05T1
cells as described.15 Samples of tumour tissue were
sliced to 5 mm and placed immediately in PLPD.
Lixation and subsequent processing were as for
human tissues.
Human tissues
Colorectal and breast tissue were collected on ice
from the operating room and taken directly to the
laboratory, where 3-5 mm tissue blocks were placed
in PLP and PLPD and allowed to fix at 4°C
overnight. After fixation for 24—36 h, tissues were
washed overnight in running tap water. Dehyd¬
ration through graded alcohols, clearing in chloro¬
form, and paraffin wax impregnation at 56°C were
performed over 20 h. Three pm sections were dried
at 56°C.
Immunocytochemistry
Rat monoclonal antibody Y13-259 was purified
by ammonium sulphate precipitation from serum-
free culture supernatant and dialysed enhaustively
against PBS. Immunoglobulin concentration in this
material was measured by radial immunodiffu¬
sion16 using purified rat immunoglobulin (Sigma)
as standard.
Dewaxed sections were rehydrated through
graded alcohols to water and then rinsed in 10 mm
Tris-buffered isotonic saline (TBS) at pH 7-6. A
three-stage streptavidin-biotin-peroxidase com¬
plex (ABC)17 immunostaining method was used.
Y13-259 was applied to sections for 1 h in concen¬
trations of 5, 25, 50, 100, and 200//g/ml in TBS
containing 10 per cent normal goat serum (TBS/
NGS). Biotinylated goat anti-rat antibody (Sigma)
1/50 in TBS/NGS was applied for 30 min. These
stages were each followed by two 5-min washes in
TBS. Streptavidin-biotin-peroxidase (ABC) com¬
plex (Amersham International) 1/200 in TBS was
applied for 15 min. After three 5-min TBS washes,
sections were developed with diaminobenzidine-
H202 in Tris-buffered 0 01 m imidazole (pH 7-6).
Negative controls included omission of Y13-259
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Fig. 1—(a) FHO 5T1 cells.(b) CF1L cells. Both fixed in PLPD, embedded in agar and paraffin. Immunostaining with Y13-259, 50 pg/ml, ABC
detection
Fig. 2—FHO 5T1 cells growing as a tumour in an immunosuppressedmouse, (a) Immunostaining with Y13-259,50 ug/ml. (b) Y13-259 replaced
by non-immune rat IgG, 50 p.g/ml as primary antibody. Both ABC detection
Fig. 3—Human breast tissue fixed in PLPD, paraffin embedded. Invasive carcinoma cells adjacent to benign parenchyma show strong positive
staining while benign epithelial elements do not. Immunostaining with Y13-259, 50 ug/ml, ABC detection
Fig. 4—Human colonic adenoma and adjacent normalmucosa fixed in PLPD, paraffin embedded. The adenoma shows staining while adjacent
mucosa does not. Immunostaining with Y13-259, 100 pg/ml, ABC detection
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same concentration of polyclonal rat immunoglo¬
bulins (Sigma) previously absorbed with acetone-
extracted human liver powder.18 A negative control
of a different type was provided by the CHL cell
line, which expresses p21 ras at barely detectable
levels.
In some instances, ABC complex was replaced by
light-microscopy grade streptavidin-colloidal gold
complex (Janssens) diluted 1/50 in TBS. After three
5-min TBS washes, fixation for 15 min in 2 per cent
glutaraldehyde in PBS, pH 7-6, 10 min in running
tap water, and six 3-min washes in DDW, sections
were exposed to 1-3 cycles of silver enhancement
with Janssens' 'IntensE' kit according to the manu¬
facturer's instructions. In an attempt to optimize
sensitivity of this immunogold-silver staining
(IGSS) protocol, some sections were immersed in
Lugol's iodine and sodium thiosulphate before
the first-layer antibody was applied, following
described empirical procedures.19'20
RESULTS
Cell lines and experimental tumours
Immunostaining of PLPD-fixed agar and
paraffin-embedded FEI05T1 cells with Y13-259
produced clear linear cell-membrane-associated
immunostaining (Fig. la) which was absent from
the parental CHL cells (Fig. 1 b). Similarmembrane
staining was obtained in paraffin sections of PLPD-
fixed FH05T1 tumours growing in immune de¬
ficient mice (Fig. 2a). Replacement of Y13-259
with non-immune rat immunoglobulin at the same
concentration abolished immunostaining (Fig. 2b).
Faint cytoplasmic staining was also usually present,
and it was our impression that this was accentuated
and membrane localization diminished in tissues
held at room temperature for 10 min prior to fixa¬
tion in an attempt to reconstruct fixation conditions
more likely to pertain for human operative speci¬
mens. Adjacent subcutaneous tissues of the host
mice did not show staining. Similar results were
obtained with ABC and IGSS detection systems.
Although claimed to increase IGSS sensitivity, even
brief pretreatment (5 s) with Lugol's iodine solution
abolished all Y13-259 immunoreactivity, whatever
detection system was used. Using the IntensE kit, it
was possible by repeated application of freshly-
mixed intensifying solution (up to three times) to
develop stronger staining but only at the cost of
increased background. No staining occurred when
Y13-259 was omitted or replaced by non-immune
rat immunoglobulin at the same concentration.
Human breast tissues
Tissues studied included normal parenchyma,
benign but pathological tissue, and carcinomas. In
general, after PLPD fixation, in situ and invasive
carcinomas showed strong positive staining with
Y13-259. Such staining was absent in negative con¬
trols. Frequently, staining of benign parenchymal
elements in the same cases was either faint or absent.
An example of this pattern is shown in Fig. 3. Unlike
FH05T1 cells and derived experimental tumours,
staining seen in human material was usually cyto¬
plasmic, with membrane accentuation in some
instances. A proportion of nuclei showed immuno¬
staining. This feature was not seen in FH05T1 cells
whether growing in vivo or in vitro. In normal breast
parenchyma, more intense Y13-259 staining was
associated with myoepithelial than with epithelial
cells.
PLPD gave better preservation of morphology
and immunoreactivity than PLP. In part, the better
preservation of antigenicity probably reflects the
lower concentration ofparaformaldehyde in PLPD.
Reducing the concentration of paraformaldehyde
in PLP from 2 to 1 per cent gives stronger Y13-259
immunoreactivity in FH05T1 cells but worse
morphology. Carcinoma tissues fixed in Carson's
fluid seldom showed staining with Y13-259 and
never to the same extent shown by the same tissues
fixed in PLPD.
Human colorectal tissues
Immunostaining with Y13-259 in colon was
analogous to that observed in breast tissue. Normal
colorectal mucosa showed very faint or absent
staining, as did muscularis and connective tissue. In
contrast, adenomas showed specific staining of
tumour cells, a sharp transition occurring between
negative normal mucosa and the strongly staining
cells of the adenoma (Fig. 4). Staining was diffusely
cytoplasmic in most cases, but as in the breast nu¬
clear staining was occasionally observed. Specific
membrane staining did not occur. Adenocarci¬
nomas also showed specific staining of similar
character, most frequently all cells showing diffuse
cytoplasmic stain. In a few cases, heterogeneity of
tumour cells was obvious, some cells being strongly
stained whilst others were negative. Tumour stroma
and muscle were negative or very faintly stained;
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